[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 232
1. Thomas L, Dalle S: [Pathology of the eyelid in elderly patients]. J Fr Ophtalmol; 2006 Jun;29(6):672-86
MedlinePlus Health Information. consumer health - Eyelid Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Illustrated review centered on diagnosis of the usual aspects and pitfalls of eyelid pathology divided into semiological chapters (tumors, blisters, erythema, etc.).
  • It is mainly centered on skin cancers (basal cell carcinoma, squamous cell carcinoma, adnexal carcinomas, and melanoma).
  • A number of rare diseases deserve mention since their presence could lead to the diagnosis of internal or systemic diseases (dermatomyositis, necrobiotic xanthogranuloma, Erdheim-Chester, etc.).
  • In such conditions, early diagnosis is often based on the observation of isolated periocular symptoms.
  • CONCLUSIONS: Even though topographic dermatology is a somewhat reductive vision of skin diseases, pathology of the eyelids deserves special mention because of its polymorphism as well as its diagnostic and/or therapeutic significance.
  • [MeSH-major] Eyelid Diseases / diagnosis
  • [MeSH-minor] Aged. Eyelid Neoplasms / diagnosis. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16885900.001).
  • [ISSN] 1773-0597
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 123
  •  go-up   go-down


2. Tarallo M, Cigna E, Frati R, Delfino S, Innocenzi D, Fama U, Corbianco A, Scuderi N: Metatypical basal cell carcinoma: a clinical review. J Exp Clin Cancer Res; 2008;27:65
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for metatypical basal cell carcinoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metatypical basal cell carcinoma: a clinical review.
  • BACKGROUND: Metatypical cell carcinoma can be considered as a new entity of skin cancer, being an intermediate typology between basal cell carcinomas and squamous cell carcinomas.
  • The behaviour of the metatypical cell carcinoma lies between these two varieties of skin cancer.
  • It is difficult to perform a differential diagnosis based on morphological and clinical features - therefore it is only possible by accurate histology.
  • METHODS: The authors have retrospectively analysed clinical records of 240 patients who were affected by metatypical skin cancer and who were treated by surgery, radiotherapy and chemotherapy.
  • CONCLUSION: In this manuscript, the authors have emphasised the importance of conducting a differential diagnosis, and the importance of the specific treatment for metatypical skin cancer, even though more clinical studies and long-term follow-ups are required before establishing specific guidelines.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 2001 Feb;44(2):224-30 [11174379.001]
  • [Cites] Plast Reconstr Surg. 2001 Apr 1;107(4):942-7 [11252086.001]
  • [Cites] Plast Reconstr Surg. 2002 Apr 1;109(4):1466-7 [11965016.001]
  • [Cites] Br J Dermatol. 2002 Apr;146 Suppl 61:1-6 [11966724.001]
  • [Cites] Virchows Arch. 2002 Dec;441(6):551-8 [12461611.001]
  • [Cites] Otolaryngol Head Neck Surg. 2003 May;128(5):663-73 [12748559.001]
  • [Cites] Dermatol Surg. 2003 Jul;29(7):700-11 [12828693.001]
  • [Cites] Dermatol Surg. 2003 Aug;29(8):830-2; discussion 833 [12859383.001]
  • [Cites] J Craniomaxillofac Surg. 2004 Feb;32(1):16-8 [14729044.001]
  • [Cites] Dermatol Surg. 2004 Feb;30(2 Pt 2):248-52 [14871217.001]
  • [Cites] Br J Ophthalmol. 2004 Mar;88(3):358-60 [14977769.001]
  • [Cites] Acta Derm Venereol. 2004;84(1):44-7 [15040477.001]
  • [Cites] Arch Facial Plast Surg. 2004 May-Jun;6(3):158-61 [15148122.001]
  • [Cites] Br J Oral Maxillofac Surg. 2004 Aug;42(4):311-4 [15225948.001]
  • [Cites] Arch Dermatol. 1965 Dec;92(6):635-7 [5846318.001]
  • [Cites] Br J Dermatol. 1973 Jul;89(1):37-43 [4788317.001]
  • [Cites] Ophthalmologica. 1983;187(1):51-8 [6877760.001]
  • [Cites] Arkh Patol. 1983;45(6):35-9 [6625927.001]
  • [Cites] J Am Acad Dermatol. 1984 Oct;11(4 Pt 1):557-62 [6490979.001]
  • [Cites] Dermatologica. 1985;171(1):21-6 [2411609.001]
  • [Cites] Arch Dermatol. 1987 Mar;123(3):340-4 [3813602.001]
  • [Cites] J Dermatol Surg Oncol. 1987 May;13(5):556-7 [3571694.001]
  • [Cites] J Dermatol Surg Oncol. 1988 Jun;14(6):600-2 [3372843.001]
  • [Cites] Dermatol Clin. 1988 Jul;6(3):397-405 [3048822.001]
  • [Cites] Mod Pathol. 1991 May;4(3):325-30 [2068058.001]
  • [Cites] J Am Acad Dermatol. 1992 Jan;26(1):1-26 [1732313.001]
  • [Cites] Pathol Res Pract. 1991 Dec;187(8):978-85 [1792194.001]
  • [Cites] J Am Acad Dermatol. 1992 Jun;26(6):976-90 [1607418.001]
  • [Cites] J Am Acad Dermatol. 1992 Aug;27(2 Pt 1):241-8 [1430364.001]
  • [Cites] J Invest Dermatol. 1994 Jun;102(6):6S-9S [8006441.001]
  • [Cites] Cancer. 1995 Jan 15;75(2 Suppl):667-73 [7804993.001]
  • [Cites] Arkh Patol. 1994 Jul-Aug;56(4):35-8 [7848103.001]
  • [Cites] Ann Chir Plast Esthet. 1994 Apr;39(2):176-83 [7872634.001]
  • [Cites] Am J Surg. 1995 Nov;170(5):446-50 [7485729.001]
  • [Cites] Laryngoscope. 1996 Feb;106(2 Pt 1):156-8 [8583845.001]
  • [Cites] Am J Dermatopathol. 1996 Feb;18(1):35-42 [8721589.001]
  • [Cites] Neurosurgery. 1997 Jul;41(1):279-81; discussion 281-2 [9218319.001]
  • [Cites] J Am Acad Dermatol. 1997 Sep;37(3 Pt 1):430-7 [9308559.001]
  • [Cites] Clin Plast Surg. 1997 Oct;24(4):627-36 [9342506.001]
  • [Cites] Clin Plast Surg. 1997 Oct;24(4):673-86 [9342510.001]
  • [Cites] J Cutan Pathol. 1998 Mar;25(3):153-9 [9550314.001]
  • [Cites] Br J Plast Surg. 1999 Jan;52(1):24-8 [10343586.001]
  • [Cites] Lancet. 2004 Nov 13-19;364(9447):1766-72 [15541449.001]
  • [Cites] Semin Cutan Med Surg. 2004 Sep;23(3):167-73 [15584682.001]
  • [Cites] Cancer. 2005 Jul 1;104(1):170-5 [15929123.001]
  • [Cites] Br J Plast Surg. 2005 Sep;58(6):795-805 [16086990.001]
  • [Cites] J Am Acad Dermatol. 2005 Sep;53(3):464-8 [16112354.001]
  • [Cites] J Plast Reconstr Aesthet Surg. 2007;60(1):41-7 [17126265.001]
  • [Cites] Eur J Dermatol. 2000 Jun;10(4):315-6 [10939863.001]
  • [Cites] Br J Oral Maxillofac Surg. 2000 Oct;38(5):477-9 [11010777.001]
  • [Cites] J Natl Compr Canc Netw. 2004 Jan;2(1):2 [19777690.001]
  • (PMID = 18992138.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 55
  • [Other-IDs] NLM/ PMC2585560
  •  go-up   go-down


3. Ch'ng S, Wallis RA, Yuan L, Davis PF, Tan ST: Mast cells and cutaneous malignancies. Mod Pathol; 2006 Jan;19(1):149-59
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This paper reviews the role of mast cells in the development and progression of basal cell carcinoma, squamous cell carcinoma and malignant melanoma.
  • Upon irradiation of the skin, trans-urocanic acid in the epidermis isomerizes to cis-urocanic acid, which stimulates neuropeptide release from neural c-fibers.
  • These neuropeptides in turn trigger histamine secretion from mast cells, leading to suppression of the cellular immune system. (2) Angiogenesis: Mast cells are the major source of vascular endothelial growth factor in basal cell carcinoma and malignant melanoma.
  • Vascular endothelial growth factor is one of the most potent angiogenic factors, which also induces leakage of other angiogenic factors across the endothelial cell wall into the matrix.
  • Mast cell proteases reorganize the stroma to facilitate endothelial cell migration.
  • As well, heparin, the dominant mast cell proteoglycan, assists in blood-borne metastasis. (3) Degradation of extracellular matrix: Through its own proteases, and indirectly via interaction with other cells, mast cells participate in degradation of the matrix, which is required for tumor spread. (4) Mitogenesis: Mast cell mediators including fibroblast growth factor-2 and interleukin-8 are mitogenic to melanoma cells.
  • Emerging data, however, also suggest that mast cells might, in fact, have opposing roles in tumor biology, and the microenvironment could polarize mast cells to possess either promoting or inhibitory effects on tumors.
  • [MeSH-major] Mast Cells / physiology. Skin Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Basal Cell / blood. Carcinoma, Basal Cell / blood supply. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / blood. Carcinoma, Squamous Cell / blood supply. Carcinoma, Squamous Cell / pathology. Humans. Melanoma / blood. Melanoma / blood supply. Melanoma / pathology. Neovascularization, Pathologic / physiopathology. Vascular Endothelial Growth Factor A / blood

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258517.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  • [Number-of-references] 71
  •  go-up   go-down


Advertisement
4. Fabbrocini G, Triassi M, Mauriello MC, Torre G, Annunziata MC, De Vita V, Pastore F, D'Arco V, Monfrecola G: Epidemiology of skin cancer: role of some environmental factors. Cancers (Basel); 2010;2(4):1980-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of skin cancer: role of some environmental factors.
  • The incidence rate of melanoma and non-melanoma skin cancer entities is dramatically increasing worldwide.
  • Exposure to UVB radiation is known to induce basal and squamous cell skin cancer in a dose-dependent way and the depletion of stratospheric ozone has implications for increases in biologically damaging solar UVB radiation reaching the earth's surface.
  • In humans, arsenic is known to cause cancer of the skin, as well as cancer of the lung, bladder, liver, and kidney.
  • SCC and BCC (squamous and basal cell carcinoma) have been reported to be associated with ingestion of arsenic alone or in combination with other risk factors.
  • Higher temperatures accompanying climate change may lead, among many other effects, to increasing incidence of skin cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24281212.001).
  • [ISSN] 2072-6694
  • [Journal-full-title] Cancers
  • [ISO-abbreviation] Cancers (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ PMC3840456
  •  go-up   go-down


5. Eide MJ, Weinstock MA, Dufresne RG Jr, Neelagaru S, Risica P, Burkholder GJ, Upegui D, Phillips KA, Armstrong BK, Robinson-Bostom L: Relationship of treatment delay with surgical defect size from keratinocyte carcinoma (basal cell carcinoma and squamous cell carcinoma of the skin). J Invest Dermatol; 2005 Feb;124(2):308-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship of treatment delay with surgical defect size from keratinocyte carcinoma (basal cell carcinoma and squamous cell carcinoma of the skin).
  • Larger keratinocyte carcinoma (KC) lesions are associated with higher morbidity.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2001 May;37(7):843-8 [11313171.001]
  • [Cites] Br J Dermatol. 2001 Mar;144(3):476-83 [11260002.001]
  • [Cites] Dermatol Surg. 2001 Nov;27(11):955-9 [11737130.001]
  • [Cites] Br J Dermatol. 2002 Jul;147(1):48-54 [12100184.001]
  • [Cites] Arch Dermatol. 2002 Aug;138(8):1043-51 [12164742.001]
  • [Cites] Melanoma Res. 2002 Aug;12(4):389-94 [12170189.001]
  • [Cites] Ann Plast Surg. 2002 Oct;49(4):439-42 [12370654.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Br J Dermatol. 2004 Jul;151(1):141-7 [15270883.001]
  • [Cites] Br J Psychiatry. 1967 Jan;113(494):89-93 [6029373.001]
  • [Cites] J Dermatol Surg Oncol. 1981 Apr;7(4):311-6 [7240532.001]
  • [Cites] Prog Clin Biol Res. 1984;156:169-79 [6473424.001]
  • [Cites] J Psychosom Res. 1985;29(2):139-53 [4009515.001]
  • [Cites] J Am Acad Dermatol. 1988 Mar;18(3):591-8 [3351022.001]
  • [Cites] J Dermatol Surg Oncol. 1989 Mar;15(3):315-28 [2646336.001]
  • [Cites] Eur J Surg Oncol. 1989 Apr;15(2):143-8 [2703058.001]
  • [Cites] Arch Dermatol. 1991 Mar;127(3):356-61 [1998366.001]
  • [Cites] J Am Acad Dermatol. 1991 Jan;24(1):1-13 [1999506.001]
  • [Cites] Postgrad Med. 1991 Mar;89(4):151-2, 155-8 [2000349.001]
  • [Cites] Ann R Coll Surg Engl. 1991 Jul;73(4):248-52 [1863047.001]
  • [Cites] J Dermatol Surg Oncol. 1991 Sep;17(9):713-8 [1890243.001]
  • [Cites] Cancer. 1991 Nov 1;68(9):2064-8 [1913555.001]
  • [Cites] Dermatol Surg. 1996 Mar;22(3):255-61 [8599737.001]
  • [Cites] J Am Acad Dermatol. 1997 Sep;37(3 Pt 1):422-9 [9308558.001]
  • [Cites] Arch Dermatol. 1999 Mar;135(3):269-74 [10086447.001]
  • [Cites] Arch Dermatol. 1999 Mar;135(3):339-40 [10086457.001]
  • [Cites] J Clin Epidemiol. 1999 Nov;52(11):1111-6 [10527006.001]
  • [Cites] Br J Dermatol. 1999 Nov;141(5):783-7 [10583157.001]
  • [Cites] Br J Dermatol. 1999 Nov;141(5):876-9 [10583170.001]
  • [Cites] Int J Cancer. 2000 May 20;89(3):271-9 [10861504.001]
  • [Cites] Int J Cancer. 2000 May 20;89(3):280-5 [10861505.001]
  • [Cites] Arch Dermatol. 2001 Aug;137(8):1055-8 [11493098.001]
  • (PMID = 15675948.001).
  • [ISSN] 0022-202X
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / K24 MH063975; United States / NCI NIH HHS / CA / R01 CA078800; United States / AHRQ HHS / HS / T32 HS000011; United States / NCI NIH HHS / CA / CA 78800
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS12744; NLM/ PMC1613794
  •  go-up   go-down


11. Costantino D, Lowe L, Brown DL: Basosquamous carcinoma-an under-recognized, high-risk cutaneous neoplasm: case study and review of the literature. J Plast Reconstr Aesthet Surg; 2006;59(4):424-8
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for basosquamous carcinoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basosquamous carcinoma-an under-recognized, high-risk cutaneous neoplasm: case study and review of the literature.
  • Basosquamous carcinoma of the skin is a relatively rare cutaneous neoplasm that has been shown to have significant metastatic potential.
  • Histopathologists debate whether these lesions arise de novo or differentiate from pre-existing basal cell carcinomas.
  • We present a case in which a longstanding lesion initially diagnosed as basal cell carcinoma was later found to have basosquamous histology and regional metastases.
  • Review of the literature reveals a metastatic rate greater than that of basal cell and squamous cell carcinoma, and identifies several important characteristics that impact prognosis after surgical resection.
  • For physicians treating carcinomas of the skin, it is important to understand the natural history and proper treatment of this aggressive neoplasm.
  • [MeSH-major] Carcinoma, Basosquamous / diagnosis. Carcinoma, Squamous Cell / diagnosis. Foot Diseases / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Lymphatic Metastasis / diagnosis. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Foot Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16756261.001).
  • [ISSN] 1748-6815
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 15
  •  go-up   go-down


12. Mitsuhashi T, Itoh T, Shimizu Y, Ban S, Ogawa F, Hirose T, Shimizu M: Squamous cell carcinoma of the skin: dual differentiations to rare basosquamous and spindle cell variants. J Cutan Pathol; 2006 Mar;33(3):246-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the skin: dual differentiations to rare basosquamous and spindle cell variants.
  • Basosquamous carcinoma (BSC) is defined as a tumor containing the areas of both basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) with a transition zone linking the two.
  • Spindle cell squamous carcinoma (SCSC) may have a variable component of conventional SCC and spindle cells.
  • Grossly, the lesion measured 8.5 x 6.0 x 1.8 cm and consisted of a gray-white and focally black tumor.
  • Microscopically, a non-ulcerated upper part of the tumor consisted of large polygonal squamoid cells with occasional keratinization (SCC), trabecular growth of basaloid cells with peripheral palisading (BCC), and an area in which both the components were intermingled.
  • The rest of the tumor was a myxoid area with elongated fusiform spindle cells, which appeared to arise from conventional SCC.
  • Immunohistochemically, the tumor cells in the SCSC (both conventional and spindle cell) area co-expressed CAM5.2, and vimentin.
  • Ber-EP4 was positive in the BCC area with the transition zone of SCC and BCC showing diminished staining.
  • To our knowledge, this is the first case report of SCC of the skin that has dual differentiations to BSC and SCSC.
  • [MeSH-major] Carcinoma / pathology. Carcinoma, Basosquamous / pathology. Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Biomarkers, Tumor / analysis. Cell Transformation, Neoplastic. Female. Humans. Immunohistochemistry. Neoplasms, Multiple Primary

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16466514.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


13. Han A, Penrose C, Goldsmith A, Marmur ES: Case-based considerations in the treatment of actinic keratoses: utilizing combination or sequential therapy with 5-fluorouracil cream and destructive treatments. J Drugs Dermatol; 2010 Jul;9(7):864-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Actinic keratoses are premalignant lesions that increase in frequency with each decade of life and have the potential to progress to squamous cell carcinoma.
  • Non-melanoma skin cancers, such as squamous cell carcinoma and basal cell carcinoma, also represent sun-related conditions that require early and aggressive treatment.
  • The following case-based review represents typical situations where multiple treatments were combined to manage actinic keratosis, squamous cell carcinoma and basal cell carcinoma in patients over an extended treatment period.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Fluorouracil / administration & dosage. Keratosis, Actinic / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / therapy. Combined Modality Therapy. Cryotherapy. Female. Humans. Male. Middle Aged. Photochemotherapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20677546.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Perrem K, Lynch A, Al Nooh F, Leader M, Elaine Kay: The different telomere lengths in basal and squamous cell carcinomas also differ between the nontransplant and renal transplant population. Hum Pathol; 2008 Jul;39(7):1034-41
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The different telomere lengths in basal and squamous cell carcinomas also differ between the nontransplant and renal transplant population.
  • Renal transplant recipients incur markedly higher rates of nonmelanoma skin cancer, including both basal and squamous cell carcinoma, by unknown mechanisms that are thought to be activated by long-term immunosuppression.
  • These tumors typically arise in sun-exposed areas of the skin and are biologically more aggressive in renal transplant recipients compared with nontransplant patients.
  • Interestingly also, the incidence of squamous cell carcinoma is generally 2- to 3-fold higher than that of basal cell carcinoma in renal transplant recipients, which is a reversal of the trend in the nontransplant population.
  • We have shown in a previous report that the increased incidence of squamous cell carcinoma in renal transplant patients is characterized by increased telomere lengths when compared with the same tumors in the nontransplant population.
  • In our current study, we performed a similar analysis of a cohort of 35 basal cell carcinoma samples from both the renal transplant and nontransplant patient groups.
  • We find that, in contrast to the situation in squamous cell carcinoma, the telomeres of the basal cell carcinomas in renal transplant recipients are in fact shorter than their counterparts in the nontransplant population, but also that these lengths are considerably longer in both cases than their squamous cell counterparts.
  • This is the first report to comprehensively show that the telomere lengths significantly differ between basal and squamous cell carcinomas.
  • These data also suggest that future treatment strategies for nonmelanoma skin cancers that are based upon telomerase inhibition, including those arising in transplant patients, may require different approaches for these two different skin lesions.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Kidney Transplantation. Skin Neoplasms / pathology. Telomere / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Female. Humans. Immunocompromised Host. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18482746.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


15. Wilkins K, Dolev JC, Turner R, LeBoit PE, Berger TG, Maurer TA: Approach to the treatment of cutaneous malignancy in HIV-infected patients. Dermatol Ther; 2005 Jan-Feb;18(1):77-86
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients infected with human immunodeficiency virus (HIV) have an increased risk of developing skin cancers.
  • This article will review and discuss management issues for the following malignancies: lymphomas, malignant melanoma, basal cell carcinoma, squamous cell carcinoma, and Kaposi's sarcoma.
  • [MeSH-major] HIV Infections / complications. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy
  • [MeSH-minor] Carcinoma, Basal Cell / complications. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Humans. Lymphoma / complications. Lymphoma / diagnosis. Lymphoma / therapy. Melanoma / complications. Melanoma / diagnosis. Melanoma / therapy. Sarcoma, Kaposi / complications. Sarcoma, Kaposi / diagnosis. Sarcoma, Kaposi / therapy

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15842615.001).
  • [ISSN] 1396-0296
  • [Journal-full-title] Dermatologic therapy
  • [ISO-abbreviation] Dermatol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 148
  •  go-up   go-down


16. Watkins J: Dermatology and the community nurse: actinic (solar) keratosis. Br J Community Nurs; 2010 Jan;15(1):6, 8, 10-1
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They are then able to check other sun-exposed areas such as the face, ears, scalp, back and limbs to discover any other lesions or more serious problems of basal cell carcinoma, squamous cell carcinoma or malignant melanoma the would require referral, sometimes urgently, to a dermatologist for full assessment and treatment.
  • [MeSH-major] Keratosis / nursing. Skin Neoplasms / nursing. Sunlight / adverse effects
  • [MeSH-minor] Community Health Nursing. Diagnosis, Differential. Humans. Nursing Diagnosis. Protective Clothing. Risk Factors. Sunscreening Agents

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20216512.001).
  • [ISSN] 1462-4753
  • [Journal-full-title] British journal of community nursing
  • [ISO-abbreviation] Br J Community Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Sunscreening Agents
  • [Number-of-references] 13
  •  go-up   go-down


17. Honeycutt KA, Waikel RL, Koster MI, Wang XJ, Roop DR: The effect of c-myc on stem cell fate influences skin tumor phenotype. Mol Carcinog; 2010 Apr;49(4):315-9
Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of c-myc on stem cell fate influences skin tumor phenotype.
  • Nonmelanoma skin cancers (NMSCs) consist of a variety of tumor types including basal cell carcinoma, squamous cell carcinoma, a variety of hair follicle tumors, and sebaceous gland tumors.
  • Our goal in the current study was to determine if alterations in the commitment of multipotent stem cells to different cell fates would influence tumor phenotype.
  • [MeSH-major] Proto-Oncogene Proteins c-myc / genetics. Skin Neoplasms / genetics. Skin Neoplasms / pathology. Stem Cells / pathology
  • [MeSH-minor] 9,10-Dimethyl-1,2-benzanthracene / toxicity. Adenocarcinoma, Sebaceous / pathology. Animals. Carcinogens / toxicity. Cell Differentiation / genetics. Cell Lineage / genetics. Crosses, Genetic. Female. Heterozygote. Male. Mice. Mice, Inbred ICR. Mice, Inbred Strains. Mice, Transgenic. Multipotent Stem Cells / pathology. Papilloma / pathology. Phenotype. Sebaceous Gland Neoplasms / pathology. Tetradecanoylphorbol Acetate / pharmacology. Transgenes

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20146250.001).
  • [ISSN] 1098-2744
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / AR47898; United States / NCI NIH HHS / CA / CA09197; United States / NCI NIH HHS / CA / CA105491; United States / NCI NIH HHS / CA / CA52607; United States / NCI NIH HHS / CA / CA79998
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Proto-Oncogene Proteins c-myc; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


18. Stranahan D, Cherpelis BS, Glass LF, Ladd S, Fenske NA: Immunohistochemical stains in Mohs surgery: a review. Dermatol Surg; 2009 Jul;35(7):1023-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: During Mohs surgery, there are instances in which residual tumor cells may be difficult to detect, thereby increasing the risk of incomplete excision and tumor recurrence.
  • RESULTS: Various immunostains have proved useful in detecting tumor cells in various malignancies, including melanoma, basal cell carcinoma, squamous cell carcinoma, dermatofibrosarcoma protuberans, extramammary Paget's disease, primary cutaneous mucinous carcinoma, granular cell tumor, and trichilemmal carcinoma.
  • CONCLUSIONS: In this article, we review immunohistochemical stains that have been employed in Mohs micrographic surgery and evaluate their utility in enhancing detection of residual tumors with respect to tumor type, particularly in situations in which detection of residual tumor may be difficult.
  • [MeSH-major] Coloring Agents. Immunohistochemistry / methods. Mohs Surgery. Neoplasm, Residual / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19397647.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Coloring Agents
  • [Number-of-references] 45
  •  go-up   go-down


19. Maroldi R, Farina D, Borghesi A, Marconi A, Gatti E: Perineural tumor spread. Neuroimaging Clin N Am; 2008 May;18(2):413-29, xi
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perineural tumor spread.
  • Perineural spread (PNS) refers to the extent of tumor cells or other nonneoplastic lesions along the tissues of the nerve sheath, its overall incidence ranges from 2.5% to 5%.
  • PNS is more frequently associated with carcinoma arising from minor or major salivary glands (more often adenoid cystic carcinoma), mucosal or cutaneous squamous cell carcinoma, basal cell carcinoma, melanoma, lymphoma, and sarcoma.
  • Therefore, radiologists must be aware of the relevant cranial nerve anatomy and thoroughly scrutinize not only the nerves close to the primary tumor site but also the whole neural pathways that can be accessed by PNS.
  • Equally critical is knowledge of the radiologic appearance of perineural tumor extension and the best imaging strategies to detect PNS.
  • [MeSH-major] Cranial Nerve Neoplasms / diagnosis. Cranial Nerve Neoplasms / secondary. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / secondary
  • [MeSH-minor] Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18466839.001).
  • [ISSN] 1052-5149
  • [Journal-full-title] Neuroimaging clinics of North America
  • [ISO-abbreviation] Neuroimaging Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 60
  •  go-up   go-down


20. Yenidunya MO, Demirseren ME, Ceran C: Bilobed flap reconstruction in infraorbital skin defects. Plast Reconstr Surg; 2007 Jan;119(1):145-50
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilobed flap reconstruction in infraorbital skin defects.
  • Improper closure of skin defects involving this region may lead to deformity in the lower lid and to ectropion.
  • This report presents the authors' experience with 15 patients who had infraorbital skin defects reconstructed with the bilobed flap from the zygomatic and lateral cheek regions.
  • Pathologic diagnoses included basal cell carcinoma, squamous cell carcinoma, melanoma, and hemangioma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17255668.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Son KD, Kim TJ, Lee YS, Park GS, Han KT, Lim JS, Kang CS: Comparative analysis of immunohistochemical markers with invasiveness and histologic differentiation in squamous cell carcinoma and basal cell carcinoma of the skin. J Surg Oncol; 2008 Jun 1;97(7):615-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of immunohistochemical markers with invasiveness and histologic differentiation in squamous cell carcinoma and basal cell carcinoma of the skin.
  • BACKGROUND: This study evaluates several tumor-related markers to examine the expression pattern of markers according to the invasiveness and histopathologic differentiation of squamous cell carcinoma and basal cell carcinoma.
  • METHODS: Ninety-four cases of squamous cell carcinoma and 108 cases of basal cell carcinoma using tissue array in order to determine correlations between the expression of Ki-67, p53, EGFR, CD44v6, MMP-1 and MMP-3, invasiveness and histologic differentiation.
  • RESULTS: The depth of invasion showed a correlation with CD44v6 expression of tumor cell in both squamous cell carcinoma and basal cell carcinoma (P = 0.009, P = 0.036, respectively) and with the MMP-1 expression of stromal cell in squamous cell carcinoma (P = 0.010).
  • The differentiation of squamous cell carcinoma was correlated with Ki-67 index.
  • The loss of palisading arrangement in basal cell carcinoma was correlated with the MMP-1 expression of stromal cells (P = 0.045).
  • CONCLUSIONS: CD44v6 and MMP-1, expressed in tumor cells and stromal cells respectively, are significant markers associated with the invasiveness of tumors in squamous cell carcinoma and basal cell carcinoma of the skin and that it will be helpful to evaluate the invasiveness by measuring the expression of these markers.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD44 / biosynthesis. Female. Genes, erbB-1. Humans. Immunohistochemistry. Ki-67 Antigen / biosynthesis. Male. Matrix Metalloproteinase 1 / biosynthesis. Matrix Metalloproteinase 3 / biosynthesis. Middle Aged. Neoplasm Invasiveness. Tumor Suppressor Protein p53 / biosynthesis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18404670.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44 protein, human; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 3.4.24.17 / Matrix Metalloproteinase 3; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


22. Kimball KJ, Straughn JM, Conner MG, Kirby TO: Recurrent basosquamous cell carcinoma of the vulva. Gynecol Oncol; 2006 Aug;102(2):400-2
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent basosquamous cell carcinoma of the vulva.
  • BACKGROUND: Basosquamous cell carcinoma (BSC) of the vulva is a rare entity with interesting prognostic and therapeutic implications.
  • CONCLUSION: BSC is a rare disorder of the vulva.
  • The metastatic potential of this tumor is not fully understood, but likely is intermediate between squamous cell carcinoma and basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basosquamous / pathology. Carcinoma, Basosquamous / surgery. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Vulvar Neoplasms / pathology. Vulvar Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16624392.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Hatina J, Ruzicka T: [Relevance of cell culture models in cutaneous tumour biology. Part I: tumour cell lines]. Hautarzt; 2008 Jan;59(1):36-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relevance of cell culture models in cutaneous tumour biology. Part I: tumour cell lines].
  • [Transliterated title] Stellenwert der Zellkulturmodelle in kutaner Tumorbiologie. Teil I: Zelllinien tumorigen transformierter Zellen.
  • Cutaneous squamous cell carcinoma, basal cell carcinoma and melanoma, much like all other human solid tumors, result from a multi-step process in which genetic and epigenetic changes accumulate in the affected cells.
  • Cell culture models are a very valuable experimental system.
  • Tumor cell lines display similar functional hierarchy as tumors or tissues in vivo and can, consequently, provide a crucial source of minor cell subsets, like tumor stem cells.
  • Progression series of clonally related cell lines offer the opportunity to follow the process of sequential acquisition of transformation-related traits up to the development of properties with direct clinical equivalents, like tumorigenicity and metastatic competence.
  • While for most studies, human transformed cell lines are the model of choice, there are questions for which animal cell lines are strongly preferred, such as interactions between the tumor and the immune system.
  • To properly interpret the results of all experiments with classical two-dimensional cell culture, a possible danger of artifacts due to grossly unnatural environment must be constantly taken into account.
  • [MeSH-major] Cell Line, Tumor / pathology. Cell Line, Tumor / physiology. Disease Models, Animal. Skin Neoplasms / pathology. Skin Neoplasms / physiopathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2004 Jan 8;23(1):30-8 [14712208.001]
  • [Cites] Annu Rev Pathol. 2007;2:175-89 [18039097.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):441-52 [10433937.001]
  • [Cites] Am J Pathol. 2000 Jan;156(1):159-67 [10623663.001]
  • [Cites] Ann N Y Acad Sci. 2003 May;995:151-61 [12814947.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Apr 15;142(2):87-91 [12699882.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7147-57 [14612508.001]
  • [Cites] Nature. 2000 Aug 3;406(6795):532-5 [10952316.001]
  • [Cites] Anticancer Res. 1997 Nov-Dec;17(6D):4359-70 [9494534.001]
  • [Cites] Mol Carcinog. 1998 Nov;23(3):144-58 [9833775.001]
  • [Cites] J Surg Res. 1995 Feb;58(2):165-74 [7861768.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):3075-86 [8674065.001]
  • [Cites] Cancer Res. 1990 Apr 15;50(8):2296-302 [2156614.001]
  • [Cites] J Cell Biochem. 1994 Feb;54(2):161-73 [8175891.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):275-84 [15803154.001]
  • [Cites] Exp Dermatol. 2007 Apr;16(4):297-301 [17359335.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Oct;5(4):365-78 [14973382.001]
  • [Cites] Exp Dermatol. 2000 Apr;9(2):104-17 [10772384.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1567-79 [11583982.001]
  • [Cites] Annu Rev Cell Dev Biol. 2006;22:339-73 [16824012.001]
  • [Cites] Arch Dermatol. 1996 Oct;132(10):1185-93 [8859029.001]
  • [Cites] J Invest Dermatol. 2006 Jun;126(6):1372-7 [16470173.001]
  • [Cites] Cancer Res. 2005 May 15;65(10 ):4320-33 [15899824.001]
  • [Cites] Nat Med. 1999 Nov;5(11):1285-91 [10545995.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jul 11;306(4):1026-36 [12821146.001]
  • [Cites] Cancer Res. 1985 Nov;45(11 Pt 2):5670-6 [4053039.001]
  • [Cites] J Invest Dermatol. 2005 Feb;124(2):401-4 [15675960.001]
  • [Cites] Exp Cell Res. 2000 Aug 1;258(2):352-60 [10896786.001]
  • [Cites] Eur J Cancer. 2007 Mar;43(5):935-46 [17320377.001]
  • [Cites] J Dtsch Dermatol Ges. 2005 Jul;3(7):493-503 [15967008.001]
  • [Cites] Cancer Res. 1991 Apr 15;51(8):2205-11 [2009539.001]
  • [Cites] Cancer Res. 1990 May 1;50(9):2840-7 [2183932.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):875-9 [8631027.001]
  • [Cites] Dtsch Med Wochenschr. 2007 Aug;132(31-32):1629-32 [17654417.001]
  • [Cites] J Invest Dermatol. 2006 Jun;126(6):1214-6 [16702970.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3759-65 [12097286.001]
  • [Cites] Cancer Res. 1980 May;40(5):1636-44 [7370995.001]
  • [Cites] Histol Histopathol. 2002;17 (3):951-9 [12168807.001]
  • [Cites] J Invest Dermatol. 2000 Dec;115(6):1095-103 [11121147.001]
  • [Cites] Melanoma Res. 1997 Aug;7 Suppl 2:S35-42 [9578415.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3837-44 [12881305.001]
  • [Cites] Nat Genet. 2000 Mar;24(3):227-35 [10700174.001]
  • [Cites] Genes Dev. 2005 Jan 15;19(2):214-23 [15625189.001]
  • [Cites] J Invest Dermatol. 2005 Feb;124(2):457-65 [15675968.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):3112-7 [8674069.001]
  • [Cites] Prostate. 1986;9(3):261-81 [3774632.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1050-5 [9448283.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5270-82 [15289333.001]
  • [Cites] Schweiz Med Wochenschr. 2000 Apr 29;130(17):617-24 [10829299.001]
  • [Cites] Hautarzt. 2004 Oct;55(10):942-51 [15349693.001]
  • [Cites] Pathologe. 1994 Jun;15(3):141-9 [8072948.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9328-37 [16230395.001]
  • [Cites] J Invest Dermatol. 2006 Jan;126(1):142-53 [16417230.001]
  • [Cites] World J Gastroenterol. 2002 Dec;8(6):976-81 [12439909.001]
  • [Cites] Int J Cancer. 1995 Mar 3;60(5):668-75 [7532159.001]
  • [Cites] Nat Med. 1997 Jul;3(7):788-92 [9212109.001]
  • [Cites] J Cell Biol. 1988 Mar;106(3):761-71 [2450098.001]
  • (PMID = 18058078.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 64
  •  go-up   go-down


24. Norval M, Cullen AP, de Gruijl FR, Longstreth J, Takizawa Y, Lucas RM, Noonan FP, van der Leun JC: The effects on human health from stratospheric ozone depletion and its interactions with climate change. Photochem Photobiol Sci; 2007 Mar;6(3):232-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Solar UVR has many harmful and some beneficial effects on individuals and, in this review, information mainly published since the previous report in 2003 (F. R. de Gruijl, J.
  • Takizawa and J. C. van der Leun, Photochem. Photobiol.
  • The skin is also exposed directly to solar UVR, and the development of skin cancer is the main adverse health outcome of excessive UVR exposure.
  • Skin cancer is the most common form of malignancy amongst fair-skinned people, and its incidence has increased markedly in recent decades.
  • Several of the genetic factors affecting susceptibility to the development of squamous cell carcinoma, basal cell carcinoma and melanoma have been identified.
  • Exposure to solar UVR down-regulates immune responses, in the skin and systemically, by a combination of mechanisms including the generation of particularly potent subsets of T regulatory cells.
  • Such immunosuppression is known to be a crucial factor in the generation of skin cancers.
  • Various strategies that can be adopted by the individual to protect against excessive exposure of the eye or the skin to sunlight are suggested.
  • [MeSH-minor] Animals. Eye / metabolism. Eye / radiation effects. Humans. Skin / metabolism. Skin / radiation effects. Vitamin D / metabolism


25. Kunte C, Konz B: [Current recommendations in the treatment of basal cell carcinoma and squamous cell carcinoma of the skin]. Hautarzt; 2007 May;58(5):419-26
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current recommendations in the treatment of basal cell carcinoma and squamous cell carcinoma of the skin].
  • [Transliterated title] Aktuelle Therapieempfehlungen für das Basalzellkarzinom und Plattenepithelkarzinom der Haut.
  • The incidence of the most common tumors of the skin, basal cell carcinoma and squamous cell carcinoma, has risen rapidly in recent years.
  • They must be able to develop therapeutic strategies adapted to the tumor and the patient.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Facial Neoplasms / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Invasiveness. Neoplasm, Residual / pathology. Neoplasm, Residual / radiotherapy. Neoplasm, Residual / surgery. Prognosis. Radiotherapy, Adjuvant. Skin / pathology. Surgical Flaps

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Strahlenther Onkol. 2001 May;177(5):240-6 [11398609.001]
  • [Cites] Facial Plast Surg. 1997 Apr;13(2):79-82 [9243982.001]
  • [Cites] Hautarzt. 2005 May;56(5):430-40 [15815888.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):722-33 [15097956.001]
  • [Cites] J Dermatol Surg Oncol. 1994 May;20(5):350 [8176049.001]
  • [Cites] Recent Results Cancer Res. 2002;160:219-24 [12079216.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):915-9 [9041153.001]
  • [Cites] BMJ. 2004 Sep 25;329(7468):705 [15364703.001]
  • [Cites] Dermatol Surg. 2000 Aug;26(8):759-64 [10940063.001]
  • [Cites] Br J Dermatol. 2000 Apr;142(4):752-7 [10792227.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):555-9 [10225444.001]
  • [Cites] Acta Derm Venereol. 2004;84(3):218-22 [15202839.001]
  • [Cites] J Am Acad Dermatol. 2007 Jan;56(1):91-5 [17190625.001]
  • [Cites] Br J Dermatol. 2006 Jun;154(6):1202-3 [16704658.001]
  • [Cites] Lancet. 1988 Apr 9;1(8589):795-7 [2895318.001]
  • [Cites] Dermatol Surg. 2006 Nov;32(11):1309-21 [17083582.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2006 Sep;20(8):926-30 [16922939.001]
  • [Cites] J Dtsch Dermatol Ges. 2006 Mar;4(3):260-2 [16626324.001]
  • [Cites] J Dermatol Surg Oncol. 1991 Jul;17(7):574-8 [1860987.001]
  • [Cites] Br J Cancer. 1997;76(1):100-6 [9218740.001]
  • [Cites] Arch Dermatol. 2004 Oct;140(10 ):1286-7 [15492202.001]
  • [Cites] Hautarzt. 1975 Dec;26(12):647-50 [1213885.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 2):642-50 [15061849.001]
  • [Cites] J Dtsch Dermatol Ges. 2006 May;4(5):441-3 [16686614.001]
  • [Cites] Hautarzt. 1995 Sep;46(9):607-14 [7591764.001]
  • [Cites] J Am Acad Dermatol. 2007 Jan;56(1):125-43 [17190630.001]
  • [Cites] J Am Acad Dermatol. 2003 Sep;49(3):483-6 [12963913.001]
  • [Cites] Eur J Dermatol. 2002 Nov-Dec;12 (6):569-72 [12459530.001]
  • [Cites] Br J Dermatol. 2002 Dec;147(6):1227-36 [12452875.001]
  • [Cites] Recent Results Cancer Res. 2002;160:240-5 [12079219.001]
  • (PMID = 17443305.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 31
  •  go-up   go-down


26. Padgett JK: Cutaneous lesions: benign and malignant. Facial Plast Surg Clin North Am; 2005 May;13(2):195-202, v
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous lesions: benign and malignant.
  • This article reviews the clinical characteristics, histology, biologic behavior, and recommended treatment for several benign and malignant lesions that may arise on the head and neck.
  • Basal and squamous cell carcinoma, lentigo maligna and lentigo maligna melanoma, dermatofibrosarcoma protuberans, and Merkel cell carcinoma are malignant lesions for which surgical excision is the recommended treatment.
  • Local flap reconstruction may be used to address the surgical defects resulting from excision of these benign and malignant conditions.
  • [MeSH-major] Head and Neck Neoplasms / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / surgery. Carcinoma, Merkel Cell / diagnosis. Carcinoma, Merkel Cell / surgery. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / surgery. Dermatofibrosarcoma / diagnosis. Dermatofibrosarcoma / surgery. Humans. Hutchinson's Melanotic Freckle / diagnosis. Hutchinson's Melanotic Freckle / surgery. Nevus, Pigmented / diagnosis. Nevus, Pigmented / surgery. Risk Factors. Scalp. Sunlight / adverse effects

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15817400.001).
  • [ISSN] 1064-7406
  • [Journal-full-title] Facial plastic surgery clinics of North America
  • [ISO-abbreviation] Facial Plast Surg Clin North Am
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


27. Rodríguez-Domínguez FJ, Hernández-Gil J, Segarra Fenoll JD, Hernández-Gil A: [Facial mutilant basosquamous carcinoma]. An Otorrinolaringol Ibero Am; 2007;34(6):549-55
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Facial mutilant basosquamous carcinoma].
  • [Transliterated title] Carcinoma basoescamoso mutilante en región facial.
  • Basosquamous carcinoma is a rare epithelial malignant neoplasm with clinical and biological features of both basal and squamous cell carcinoma.
  • This neoplasm has been characterized for years as a variant of basal cell carcinoma, although now it is widely accepted as a clinical entity.
  • The most important features of basosquamous carcinoma are its great local aggressiveness, high frequency of recurrences and its metastatic potential.
  • [MeSH-major] Carcinoma, Basosquamous / pathology. Head and Neck Neoplasms / pathology. Palliative Care / methods
  • [MeSH-minor] Anti-Bacterial Agents / therapeutic use. Face. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18293774.001).
  • [ISSN] 0303-8874
  • [Journal-full-title] Anales otorrinolaringológicos ibero-americanos
  • [ISO-abbreviation] An Otorrinolaringol Ibero Am
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


28. Geist DE, Garcia-Moliner M, Fitzek MM, Cho H, Rogers GS: Perineural invasion of cutaneous squamous cell carcinoma and basal cell carcinoma: raising awareness and optimizing management. Dermatol Surg; 2008 Dec;34(12):1642-51
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perineural invasion of cutaneous squamous cell carcinoma and basal cell carcinoma: raising awareness and optimizing management.
  • BACKGROUND: Perineural invasion (PNI) by cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC) is an infrequent but not rare complication of traditionally low-morbidity skin cancers that can lead to catastrophic sequelae; 2.5% to 14% of CSCC and approximately 3% of BCC exhibit PNI.
  • MATERIALS AND METHODS: Cases of PNI treated with MMS and radiotherapy were reviewed for recurrence, disease-free follow-up, and adverse events.
  • When managing superficial skin tumors with PNI, a multidisciplinary team including a cutaneous surgeon and a radiation oncologist familiar with PNI is recommended.
  • [MeSH-major] Bell Palsy / etiology. Carcinoma, Basal Cell / complications. Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / therapy. Neoplasms, Multiple Primary / complications. Neoplasms, Multiple Primary / therapy. Skin Neoplasms / complications. Skin Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Mohs Surgery. Neoplasm Invasiveness. Peripheral Nerves

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Bell's Palsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19018830.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Terziqi H, Tarpila E: Reconstruction of large defect of lower lip and commissure using Karapandzic flap: case report. Niger J Med; 2009 Apr-Jun;18(2):222-3
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Xeroderma Pigmentosum (XP) is a photosensitive skin disease with a high risk for developing skin malignancy.
  • We present an 18-years-old boy with XP and recurrent basal and squamous cell carcinoma of lower lip.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Lip Neoplasms / surgery. Reconstructive Surgical Procedures. Surgical Flaps. Xeroderma Pigmentosum / pathology
  • [MeSH-minor] Adolescent. Humans. Male. Neoplasm Recurrence, Local / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19630336.001).
  • [ISSN] 1115-2613
  • [Journal-full-title] Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria
  • [ISO-abbreviation] Niger J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


30. Chen T, Bertenthal D, Sahay A, Sen S, Chren MM: Predictors of skin-related quality of life after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. Arch Dermatol; 2007 Nov;143(11):1386-92
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of skin-related quality of life after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma.
  • OBJECTIVE: To identify predictors of skin-related quality of life (QOL) after treatment of nonmelanoma skin cancer (NMSC).
  • SETTING: University-affiliated private practice and a Veterans Affairs clinic.
  • MAIN OUTCOME MEASURE: Skin-related QOL, measured with the 16-item version of Skindex-16, a validated measure.
  • RESULTS: Controlling for treatment group, the strongest independent predictor of skin-related QOL after treatment of NMSC was pretreatment skin-related QOL.
  • No tumor or care characteristic (including location of tumor, size of tumor, site of therapy, or training level of treating clinician [attending physician, resident, or nurse practitioner]) was found to predict better skin-related QOL after treatment of NMSC.
  • CONCLUSIONS: Patients with better pretreatment skin-related QOL, less comorbidity, and better mental health status had better skin-related QOL after treatment of NMSC.
  • [MeSH-major] Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / therapy. Quality of Life. Skin / physiopathology. Skin Neoplasms / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Dermatol. 2007 Nov;143(11):1429-32 [18025368.001]
  • [ErratumIn] Arch Dermatol. 2008 Feb;144(2):230
  • (PMID = 18025362.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / K02 AR02203; United States / NIAMS NIH HHS / AR / K24-AR052667
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


31. Askari SK, Schram SE, Wenner RA, Bowers S, Liu A, Bangerter AK, Warshaw EM: Evaluation of prospectively collected presenting signs/symptoms of biopsy-proven melanoma, basal cell carcinoma, squamous cell carcinoma, and seborrheic keratosis in an elderly male population. J Am Acad Dermatol; 2007 May;56(5):739-47
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of prospectively collected presenting signs/symptoms of biopsy-proven melanoma, basal cell carcinoma, squamous cell carcinoma, and seborrheic keratosis in an elderly male population.
  • BACKGROUND: Presenting signs/symptoms of skin cancer may aid in earlier detection and diagnosis.
  • OBJECTIVE: We sought to compare prospectively collected, presenting signs/symptoms of malignant melanoma (MM), basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and seborrheic keratosis (SK).
  • METHODS: This analysis was part of a larger study on teledermatology involving 3039 skin neoplasms in 2152 patients at a Department of Veterans Affairs medical center.
  • At presentation, participants were asked about signs/symptoms of specific skin lesions.
  • In all, 912 biopsy-proven MM (39), BCC (411), SCC (238), and SK (224) were included in this analysis.
  • RESULTS: "No symptoms" was reported more often with MM (82%) as compared with BCC (relative risk [RR] 2.26, confidence interval [CI] 1.86, 2.75), SCC (RR 3.31, CI 2.54, 4.32), or SK (RR 2.0, CI 1.61, 2.48; all P < .0001).
  • Tenderness was more commonly reported with SCC (40%) as compared with MM (RR 15.9, CI 2.28, 110.69), SK (RR 3.0, CI 2.11, 4.39), or BCC (RR 2.6, CI 1.97, 3.38; all P < .0001).
  • Bleeding was more commonly reported with BCC (37%) as compared with SK (RR 2.3, CI 1.67, 3.20), SCC (RR 1.6, CI 1.22, 2.05), or MM (RR 29.8, CI 1.89, 469.65; all P <or= .007).
  • CONCLUSION: This study describes common signs/symptoms of BCC, SCC, and SK.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Keratosis, Seborrheic / diagnosis. Melanoma / diagnosis. Skin Diseases / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Humans. Male. Middle Aged. Prospective Studies. Skin Neoplasms / diagnosis


32. Fantini F, Gualdi G, Cimitan A, Giannetti A: Metastatic basal cell carcinoma with squamous differentiation: report of a case with response of cutaneous metastases to electrochemotherapy. Arch Dermatol; 2008 Sep;144(9):1186-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic basal cell carcinoma with squamous differentiation: report of a case with response of cutaneous metastases to electrochemotherapy.
  • BACKGROUND: Metastatic basal cell carcinoma is a rare disease with poor prognosis.
  • Electrochemotherapy is a recently described therapy that relies on the permeation of cancer cell membranes by electrical pulses to enhance cytotoxic drug penetration.
  • It has been successfully used in the treatment of primary and metastatic skin cancers.
  • We report a case of metastatic basal cell carcinoma in which electrochemotherapy was effective in inducing local regression of skin metastases.
  • OBSERVATIONS: A 75-year-old man presented with a pigmented, deeply infiltrating nodule in the right axilla manifesting as basal cell carcinoma with squamous differentiation at histopathologic examination.
  • Three successive sessions of electrochemotherapy with bleomycin sulfate were then performed on isolated skin metastases.
  • Conclusion Electrochemotherapy is an effective and well-tolerated adjunct to the therapeutic options in metastatic basal cell carcinoma, characterized by an advantageous risk-benefit ratio and minimal downtime.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / secondary. Electrochemotherapy. Skin Neoplasms / pathology. Skin Neoplasms / secondary
  • [MeSH-minor] Aged. Antibiotics, Antineoplastic / therapeutic use. Bleomycin / therapeutic use. Cell Differentiation. Humans. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18794464.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin
  •  go-up   go-down


33. Hatta N, Hirano T, Kimura T, Hashimoto K, Mehregan DR, Ansai S, Takehara K, Takata M: Molecular diagnosis of basal cell carcinoma and other basaloid cell neoplasms of the skin by the quantification of Gli1 transcript levels. J Cutan Pathol; 2005 Feb;32(2):131-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular diagnosis of basal cell carcinoma and other basaloid cell neoplasms of the skin by the quantification of Gli1 transcript levels.
  • BACKGROUND: Distinguishing basal cell carcinoma (BCC) from other benign and malignant skin tumors is sometimes a difficult task for the pathologists.
  • Because the activation of hedgehog signals and the up-regulation of its critical transcriptional factor Gli1 are well documented in BCC, a molecular technique measuring Gli1 transcripts may aide the diagnosis.
  • METHODS: Gli1 transcript levels were measured by real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) using RNA extracted from formalin-fixed, paraffin-embedded tissues of 68 cases of various skin tumors.
  • The tumors included BCC (21), squamous cell carcinoma (13), seborrheic keratoses (8), trichoepithelioma (5), eccrine poroma/porocarcinoma (4), and sebaceous epithelioma/carcinoma (2).
  • In these unambiguous cases, all BCC and trichoepithelioma tumors showed high expression of Gli1mRNA, while the expression was virtually absent in other tumors.
  • The diagnosis was discordant among three pathologists in the remaining 15 tumors.
  • Histological diagnoses included BCC, BCC with sebaceous differentiation, sebaceoma/sebaceous epithelioma, trichoblastoma, trichoepithelioma, basaloid follicular harmartoma, basosquamous carcinoma, etc.
  • CONCLUSIONS: Quantification of Gli1 transcripts by RT-PCR is helpful in discriminating BCC and trichoepithelioma from other skin tumors.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / diagnosis. Oncogene Proteins / metabolism. Skin Neoplasms / diagnosis. Transcription Factors / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Child. Diagnosis, Differential. Female. Humans. Male. Middle Aged. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Trans-Activators. Transcription, Genetic

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15606671.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Gli protein; 0 / Oncogene Proteins; 0 / RNA, Messenger; 0 / Trans-Activators; 0 / Transcription Factors
  •  go-up   go-down


34. Barrera MV, Herrera E: [Topical chemotherapy for actinic keratosis and nonmelanoma skin cancer: current options and future perspectives]. Actas Dermosifiliogr; 2007 Oct;98(8):556-62
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Topical chemotherapy for actinic keratosis and nonmelanoma skin cancer: current options and future perspectives].
  • [Transliterated title] Tratamiento quimioterápico tópico de la queratosis actínica y el cáncer cutáneo no melanoma: situación actual y perspectivas.
  • Actinic keratosis is currently considered not to be a precursor of squamous cell carcinoma but, rather, an initial stage of the disease.
  • Furthermore, the incidence of both squamous cell carcinoma and basal cell carcinoma continues to increase.
  • Topical drugs are now becoming widely used in the therapeutic management of nonmelanoma skin cancer and its precursor lesions.
  • [MeSH-major] Keratosis / drug therapy. Keratosis / etiology. Skin Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17919432.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 33
  •  go-up   go-down


35. Caccialanza M, Piccinno R, Kolesnikova L, Gnecchi L: Radiotherapy of skin carcinomas of the pinna: a study of 115 lesions in 108 patients. Int J Dermatol; 2005 Jun;44(6):513-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy of skin carcinomas of the pinna: a study of 115 lesions in 108 patients.
  • BACKGROUND: The possibility of treating skin carcinomas of the pinna with radiotherapy is somewhat under discussion and scarcely known.
  • Therefore the aim of the study was to evaluate the effectiveness and safety of dermatologic radiotherapy in a series of patients affected by basal or squamous cell carcinoma of the pinna.
  • METHODS: A retrospective study was performed on 108 patients affected by 115 carcinomas of the pinna (99 basal cell carcinomas, 16 squamous cell carcinomas) without involvement of the external auditory canal.
  • During follow up a relapse was observed in 12 lesions (all basal cell carcinomas): nine central and three marginal to the irradiation field.
  • CONCLUSIONS: The results obtained confirm the possibility of treating epithelial skin neoplasms of the pinna with dermatologic radiotherapy, which can afford high-remission percentages without damaging cartilaginous tissue.
  • [MeSH-major] Carcinoma, Basal Cell / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Ear Neoplasms / radiotherapy. Ear, External. Skin Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Esthetics. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / therapy. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15941445.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Meslemani DM, Jones L: An unusual presentation of nasal type NK/T-cell lymphoma of the nose. Laryngoscope; 2010;120 Suppl 4:S167
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual presentation of nasal type NK/T-cell lymphoma of the nose.
  • OBJECTIVES: Case report of a male with a rare nasal type NK/T cell lymphoma that presented as an aggressive nasal infection superimposed with squamous and basal cell carcinoma.
  • A review of the diagnosis, management, and prognosis nasal type NK/T cell lymphoma will be presented.
  • METHODS: Review of the literature for cases of nasal type NK/T cell lymphoma, with particular attention to its presentations.
  • RESULTS: Differential diagnosis includes aggressive infection of the nasal skin, carcinoma, and lymphoma.
  • CONCLUSION: No cases in the literature of NK/T cell lymphoma have been reported that presented with an aggressive infection with initial biopsies that revealed squamous cell and basal cell carcinoma, which led to surgical management and a definitive diagnosis of Nasal type NK/T cell lymphoma.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Lymphoma, T-Cell, Cutaneous / pathology. Nose Neoplasms / pathology
  • [MeSH-minor] Combined Modality Therapy. Diagnosis, Differential. Humans. Male. Middle Aged. Rhinitis / pathology. Sinusitis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21225765.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


37. Payette MJ, Whalen J, Grant-Kels JM: Nutrition and nonmelanoma skin cancers. Clin Dermatol; 2010 Nov-Dec;28(6):650-62
Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nutrition and nonmelanoma skin cancers.
  • The incidence of nonmelanoma skin cancer is increasing every year.
  • Basal cell carcinoma and squamous cell carcinoma are the two major types of nonmelanoma skin cancer.
  • Among other factors, understanding the potential role of nutrients in the development, progression, and treatment of nonmelanoma skin cancer is critical.
  • This contribution provides a review of the nutrients that have been more extensively investigated in the literature with regard to nonmelanoma skin cancer, including dietary fats, retinol, carotenoids, vitamin C, vitamin D, vitamin E, selenium, copper, iron, zinc, green tea, and black tea.
  • [MeSH-major] Carcinoma, Basal Cell. Carcinoma, Squamous Cell. Diet. Micronutrients / administration & dosage. Skin Neoplasms

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Green tea .
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • Hazardous Substances Data Bank. VITAMIN A .
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • Hazardous Substances Data Bank. COPPER, ELEMENTAL .
  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21034989.001).
  • [ISSN] 1879-1131
  • [Journal-full-title] Clinics in dermatology
  • [ISO-abbreviation] Clin. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dietary Fats; 0 / Micronutrients; 0 / Tea; 11103-57-4 / Vitamin A; 1406-16-2 / Vitamin D; 1406-18-4 / Vitamin E; 36-88-4 / Carotenoids; 789U1901C5 / Copper; E1UOL152H7 / Iron; H6241UJ22B / Selenium; J41CSQ7QDS / Zinc; PQ6CK8PD0R / Ascorbic Acid
  •  go-up   go-down


38. Tatiana K S C, Somers GR, Pope E, Zuker RM: Predisposing factors and outcomes of malignant skin tumors in children. Plast Reconstr Surg; 2010 Aug;126(2):508-14
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predisposing factors and outcomes of malignant skin tumors in children.
  • BACKGROUND: Although benign and metastatic tumors occur in children, primary malignant skin tumors are uncommon in the pediatric population.
  • In this study, the authors aimed to determine the incidence, risk factors, treatment, reconstruction details, and outcome of malignant skin tumors occurring in pediatric patients at the Hospital for Sick Children.
  • METHODS: The electronic database (CoPath) of the pathology department was searched for all cases of malignant skin tumors treated surgically between January of 2000 and September of 2008.
  • RESULTS: Eighteen patients had been diagnosed and treated surgically for malignant skin tumors.
  • Diagnosis of malignant melanoma was made in 14 patients, diagnosis of basal cell carcinoma was made in four patients, and diagnosis of squamous cell carcinoma was made in one patient.
  • Gorlin syndrome was an underlying predisposing condition in three patients with basal cell carcinoma.
  • All cases of basal cell carcinoma and squamous cell carcinoma underwent surgical resection and primary closure or skin graft.
  • Of the patients with malignant melanoma, seven underwent surgical excision and primary closure and five had excision and skin graft.
  • CONCLUSIONS: Malignant skin tumors are rare in children.
  • In accordance with previously published data, malignant melanoma was the most frequent tumor in our study.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Sentinel Lymph Node Biopsy / methods. Skin Neoplasms / epidemiology. Skin Neoplasms / surgery. Skin Transplantation / methods
  • [MeSH-minor] Adolescent. Age Distribution. Canada / epidemiology. Carcinoma, Basal Cell / epidemiology. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Causality. Child. Child, Preschool. Cohort Studies. Databases, Factual. Dermatology / methods. Female. Follow-Up Studies. Humans. Immunohistochemistry. Incidence. Male. Melanoma / epidemiology. Melanoma / pathology. Melanoma / surgery. Neoplasm Staging. Sex Distribution. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20375763.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Thomson P, Palamaras I, Hill V, Robles W, Stevens H: Patients are happy to be informed of their final non-melanoma skin cancer results by post. Dermatol Online J; 2010;16(1):5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients are happy to be informed of their final non-melanoma skin cancer results by post.
  • During the past year, because of increasing pressure to see more patients, we have started to write to our patients informing them in a letter of their final skin cancer histology results following surgery for non-melanoma skin cancers: basal cell carcinoma and squamous cell carcinoma only.
  • A questionnaire-based study was carried out to assess whether patients were happy to receive information concerning their non-melanoma skin cancer diagnosis in a carefully worded letter.
  • One-hundred fifty patients were involved with a diagnosis of "completely excised non-melanoma skin cancer (NMSC)" that had previously received their final diagnosis by post.
  • Eighty-seven percent felt that they had been given the cancer diagnosis in an appropriate manner; 90 percent reported that they had understood the explanation about their skin cancer.
  • In addition, 81 percent stated that they had been sufficiently involved in the discussion about their skin cancer and its treatment.
  • [MeSH-major] Carcinoma, Basal Cell / psychology. Carcinoma, Squamous Cell / psychology. Communication. Patient Acceptance of Health Care. Patient Satisfaction. Patients / psychology. Postal Service. Skin Neoplasms / psychology. Truth Disclosure

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20137747.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Cabrijan L, Lipozencić J, Batinac T, Lenković M, Stanić Zgombić Z: Influence of PUVA and UVB radiation on expression of ICAM-1 and VCAM-1 molecules in psoriasis vulgaris. Coll Antropol; 2008 Oct;32 Suppl 2:53-6
MedlinePlus Health Information. consumer health - Psoriasis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression of adhesion molecules Intercellular adhesion molecule-1 (ICAM-1) and Vascular cell adhesion molecule-1 (VCAM-1) is increased in lesional and in non-lesional skin of psoriatic patients, and play role in pathogenesis of the disease.
  • The expression of these molecules was examined by immunohistochemical method in lesional and non-lesional skin of 10 patients with psoriasis vulgaris before and after treatment.
  • After therapy, the expression of the adhesion molecules decreased together with a marked improvement of the disease.
  • Adverse reactions due to intense or long lasting UVA (PUVA) and UVB therapies are immunosuppression and damage of DNA which can lead to development of non-melanocytic skin tumors like basal cell carcinoma and squamous cell carcinoma, as well as melanoma.
  • [MeSH-major] Intercellular Adhesion Molecule-1 / radiation effects. Psoriasis / metabolism. Psoriasis / therapy. Ultraviolet Therapy. Vascular Cell Adhesion Molecule-1 / radiation effects

  • Genetic Alliance. consumer health - Psoriasis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19138007.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Vascular Cell Adhesion Molecule-1; 126547-89-5 / Intercellular Adhesion Molecule-1
  •  go-up   go-down


41. Moan J, Porojnicu AC, Dahlback A: Ultraviolet radiation and malignant melanoma. Adv Exp Med Biol; 2008;624:104-16
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultraviolet radiation and malignant melanoma.
  • Essential features of the epidemiology and photobiology of cutaneous malignant melanoma (CMM) in Norway were studied in comparison with data from countries at lower latitudes.
  • This hypothesis was supported both by latitude gradients, by time trends and by changing patterns of tumor density on different body localizations.
  • Comparisons of skin cancer data from Norway and Australia/New Zealand indicate that squamous cell carcinoma and basal cell carcinoma are mainly related to annual solar UVB fluences, while UVA fluences play a larger role for CMM.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Melanoma / epidemiology. Skin Neoplasms / epidemiology. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18348451.001).
  • [ISSN] 0065-2598
  • [Journal-full-title] Advances in experimental medicine and biology
  • [ISO-abbreviation] Adv. Exp. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 52
  •  go-up   go-down


42. Hargis AM, Baldessari AE, Walder EJ: Intraepidermal adenocarcinoma in the perianal skin of two cats, a condition resembling human extramammary Paget's disease. Vet Dermatol; 2008 Feb;19(1):31-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraepidermal adenocarcinoma in the perianal skin of two cats, a condition resembling human extramammary Paget's disease.
  • In humans, mammary and extramammary Paget's disease is an uncommon to rare manifestation of intraepidermal adenocarcinoma arising from simple epithelium, usually glandular in origin.
  • This report describes two cats with lesions in perianal skin consisting of atypical intraepidermal neoplastic cells.
  • Differential diagnoses included intraepidermal adenocarcinoma, in situ squamous or basal cell carcinoma, junctional amelanotic melanoma, and epitheliotropic tumours of histiocytic or lymphocytic origin.
  • The keratinocytes and basal cells were negative for CK8/18.
  • The clinical features, histological appearance, and immunohistochemical staining of the skin lesions were consistent with those described for human perianal extramammary Paget's disease.
  • [MeSH-major] Adenocarcinoma / veterinary. Cat Diseases / diagnosis. Perineum / pathology. Skin Neoplasms / veterinary
  • [MeSH-minor] Animals. Cats. Diagnosis, Differential. Female. Humans. Paget Disease, Extramammary

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18177290.001).
  • [ISSN] 0959-4493
  • [Journal-full-title] Veterinary dermatology
  • [ISO-abbreviation] Vet. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


43. de Haas ER, de Vijlder HC, van Reesema WS, van Everdingen JJ, Neumann HA: Quality of clinical practice guidelines in dermatological oncology. J Eur Acad Dermatol Venereol; 2007 Oct;21(9):1193-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We searched MEDLINE, PubMed, EMBASE and Cochrane literature and relevant websites of guidelines development programmes and the national dermatological society to identify evidence-based dermatological guidelines especially in the treatment of to basal cell carcinoma, squamous cell carcinoma and melanoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17894704.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


44. Zamanian A, Mahjub H, Mehralian A: Skin diseases in kidney transplant recipients. Urol J; 2006;3(4):230-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin diseases in kidney transplant recipients.
  • INTRODUCTION: The aim of this study was to evaluate the frequency of skin diseases in kidney transplant recipients.
  • The patients were examined by a dermatologist and diagnosis was made on the basis of clinical observations.
  • RESULTS: Of the patients, 226 (97%) suffered from one or more skin lesions.
  • Also, infectious and premalignant or malignant lesions (actinic keratosis, squamous cell carcinoma, and basal cell carcinoma) were seen in 48.9% and 14.2% of the patients.
  • The mean duration of immunosuppressive therapy was significantly higher in patients with infectious skin diseases (P < .001).
  • CONCLUSION: Skin lesions are a significant problem in kidney transplant recipients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17559047.001).
  • [ISSN] 1735-1308
  • [Journal-full-title] Urology journal
  • [ISO-abbreviation] Urol J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  •  go-up   go-down


45. Ban JH, Lee JK, Jin SM, Lee KC: Basaloid squamous cell carcinoma of the external auditory canal: case report. Eur Arch Otorhinolaryngol; 2007 Jun;264(6):697-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid squamous cell carcinoma of the external auditory canal: case report.
  • Basaloid squamous cell carcinoma (BSCC) is a rare malignancy, with features of both basal cell carcinoma and squamous cell carcinoma.
  • The tumor has a predilection for the upper aerodigestive tract, and has been suggested to behave more aggressively than squamous cell carcinoma (SCC).
  • Excision of the tumor was accomplished by modified lateral temporal bone resection.
  • This report describes the first case of BSCC in this location, and includes reviews of the pathologic and clinical aspects of this disease.
  • [MeSH-major] Carcinoma, Basosquamous / pathology. Ear Canal / pathology. Ear Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 2000 Sep;110(9):1479-82 [10983946.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2003 Nov-Dec;65(6):332-40 [14981326.001]
  • [Cites] Arch Otolaryngol. 1980 Nov;106(11):675-9 [6252880.001]
  • [Cites] Laryngoscope. 2004 Jul;114(7):1179-83 [15235344.001]
  • [Cites] Am J Otol. 2000 Jul;21(4):582-8 [10912706.001]
  • [Cites] J Otolaryngol. 2005 Jun;34(3):212-5 [16089230.001]
  • [Cites] Hum Pathol. 1986 Nov;17(11):1158-66 [3770734.001]
  • [Cites] J Plast Reconstr Aesthet Surg. 2006;59(4):424-8 [16756261.001]
  • (PMID = 17235532.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


46. Lehnerdt G, Manz D, Jahnke K, Schmitz KJ: [Cutaneous basosquamous cell carcinoma]. HNO; 2008 Mar;56(3):306-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cutaneous basosquamous cell carcinoma].
  • [Transliterated title] Basosquamöses Karzinom der Haut.
  • BACKGROUND: Basosquamous carcinoma (BSC) is a rare malignancy with specific histopathological features of both basal cell (BCC) and squamous cell carcinoma (SCC).
  • Therefore, the histological diagnosis is challenging.
  • In the case of the carcinoma on the forehead, a local excision was performed.
  • CONCLUSIONS: The histological diagnosis of BSC is confirmed by the use of EMA and BerEP4 immunohistological staining.
  • Clinically, BSC is a rare, aggressive skin tumor.
  • Despite the histological similarity to basal cell carcinoma, BSC has an imminent risk of metastasizing.
  • [MeSH-major] Carcinoma, Basosquamous / pathology. Carcinoma, Basosquamous / surgery. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / surgery. Otorhinolaryngologic Surgical Procedures / methods. Skin Neoplasms / pathology. Skin Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Treatment Outcome


47. Verhoeven RH, Louwman WJ, Koldewijn EL, Demeyere TB, Coebergh JW: Scrotal cancer: incidence, survival and second primary tumours in the Netherlands since 1989. Br J Cancer; 2010 Oct 26;103(9):1462-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The overall incidence rate varied around 1.5 per 1,000,000 person-years, most frequently being squamous cell carcinoma (27%), basal cell carcinoma (19%) and Bowen's disease (15%).
  • Overall 5-year relative survival was 82%, being 77% and 95% for patients with squamous and basal cell carcinoma, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Stat Med. 2000 Feb 15;19(3):335-51 [10649300.001]
  • [Cites] Urology. 2008 Nov;72(5):1139-43 [18799208.001]
  • [Cites] J Am Acad Dermatol. 2002 Jul;47(1):33-9 [12077578.001]
  • [Cites] J Urol. 1967 Jul;98(1):108-10 [6067877.001]
  • [Cites] Br J Ind Med. 1972 Apr;29(2):188-95 [5063206.001]
  • [Cites] Acta Derm Venereol. 1974;54(6):471-4 [4140663.001]
  • [Cites] Ann N Y Acad Sci. 1976;271:138-42 [1069495.001]
  • [Cites] J Urol. 1977 Jun;117(6):741-5 [559784.001]
  • [Cites] Urology. 1982 Mar;19(3):269-74 [7064253.001]
  • [Cites] Cancer. 1984 Aug 1;54(3):596-601 [6733690.001]
  • [Cites] Br J Ind Med. 1984 Nov;41(4):437-44 [6498107.001]
  • [Cites] Cancer. 1985 Feb 1;55(3):666-71 [3965115.001]
  • [Cites] Comput Programs Biomed. 1985;19(2-3):197-207 [3839736.001]
  • [Cites] Am J Public Health. 1989 Nov;79(11):1513-5 [2817163.001]
  • [Cites] Br J Ind Med. 1989 Jun;46(6):430-1 [2818983.001]
  • [Cites] Br J Urol. 1991 Oct;68(4):414-7 [1933164.001]
  • [Cites] J Urol. 1991 Nov;146(5):1299-304 [1942281.001]
  • [Cites] Cancer Causes Control. 1992 Jan;3(1):91-3 [1536920.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2759-64 [8194017.001]
  • [Cites] Occup Med (Lond). 1996 Feb;46(1):69-70 [8672799.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Mar;109(2):108-13 [10087941.001]
  • [Cites] AMA Arch Ind Health. 1959 May;19(5):530-9 [13636468.001]
  • [Cites] Br J Ind Med. 1972 Oct;29(4):394-406 [15625750.001]
  • [Cites] Ned Tijdschr Geneeskd. 2006 May 20;150(20):1108-15 [16756222.001]
  • [Cites] Arch Dermatol. 2000 Dec;136(12):1524-30 [11115165.001]
  • (PMID = 20877361.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2990603
  •  go-up   go-down


48. Dim-Jamora KC, Perone JB: Management of cutaneous tumors with mohs micrographic surgery. Semin Plast Surg; 2008 Nov;22(4):247-56

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We discuss the use of Mohs micrographic surgery for the following cutaneous tumors: basal cell carcinoma, squamous cell carcinoma, melanoma in situ, dermatofibrosarcoma protuberans, Merkel cell carcinoma, microcystic adnexal carcinoma, atypical fibroxanthoma, and sebaceous carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1996 Mar 16;347(9003):735-8 [8602006.001]
  • [Cites] J Am Acad Dermatol. 1996 Jul;35(1):82-7 [8682970.001]
  • [Cites] J Am Acad Dermatol. 1995 Feb;32(2 Pt 1):233-6 [7829708.001]
  • [Cites] Lancet. 1994 Feb 19;343(8895):433-4 [7905951.001]
  • [Cites] Cancer. 1994 Jun 15;73(12):2964-70 [8199993.001]
  • [Cites] Clin Plast Surg. 1993 Jan;20(1):149-56 [8420703.001]
  • [Cites] J Am Acad Dermatol. 1993 Nov;29(5 Pt 2):840-5 [8408823.001]
  • [Cites] Otolaryngol Clin North Am. 1993 Apr;26(2):185-202 [8460037.001]
  • [Cites] J Dermatol Surg Oncol. 1991 Aug;17(8):681-4 [1885833.001]
  • [Cites] Dermatol Clin. 1989 Oct;7(4):833-43 [2676291.001]
  • [Cites] Dermatol Clin. 1989 Oct;7(4):609-11 [2676280.001]
  • [Cites] J Dermatol Surg Oncol. 1989 Mar;15(3):315-28 [2646336.001]
  • [Cites] N J Med. 1989 May;86(5):369-73 [2739948.001]
  • [Cites] J Am Acad Dermatol. 1986 Apr;14(4):668-73 [3958277.001]
  • [Cites] Eye (Lond). 1990;4 ( Pt 1):160-8 [2323467.001]
  • [Cites] Head Neck Surg. 1983 Jan-Feb;5(3):197-203 [6841116.001]
  • [Cites] Arch Dermatol. 1974 Aug;110(2):231-2 [4853214.001]
  • [Cites] Plast Reconstr Surg. 2004 Jun;113(7):2233; author reply 2233-4 [15253235.001]
  • [Cites] Arch Dermatol. 2004 Jun;140(6):736-42 [15210467.001]
  • [Cites] Clin Plast Surg. 2004 Jan;31(1):5-31 [15022790.001]
  • [Cites] Plast Reconstr Surg. 2002 Nov;110(6):1601 [12409793.001]
  • [Cites] Dermatol Surg. 2002 Aug;28(8):656-65 [12174054.001]
  • [Cites] Semin Oncol. 2002 Aug;29(4):336-40 [12170436.001]
  • [Cites] Dermatol Surg. 2002 Jul;28(7):623-31 [12135523.001]
  • [Cites] Br J Dermatol. 2002 Jan;146(1):18-25 [11841362.001]
  • [Cites] J Am Acad Dermatol. 2001 Oct;45(4):579-86 [11568750.001]
  • [Cites] Arch Facial Plast Surg. 2001 Jul-Sep;3(3):202-6 [11497507.001]
  • [Cites] J Am Acad Dermatol. 2001 Jun;44(6):1004-9 [11369914.001]
  • [Cites] Dermatol Surg. 2001 Apr;27(4):401-8 [11298716.001]
  • [Cites] Dermatol Surg. 2000 Aug;26(8):771-84 [10940065.001]
  • [Cites] Dermatol Surg. 2000 Apr;26(4):303-7 [10759814.001]
  • [Cites] Aust N Z J Surg. 2000 May;70(5):358-61 [10830600.001]
  • [Cites] Cancer. 2000 Apr 15;88(8):1842-51 [10760761.001]
  • [Cites] Dermatol Surg. 2007 Apr;33(4):395-402 [17430372.001]
  • [Cites] Skin Therapy Lett. 2007 Mar;12(2):6-9 [17393051.001]
  • [Cites] Ophthalmology. 2007 Jan;114(1):187-92 [17140665.001]
  • [Cites] Arch Dermatol. 2006 Feb;142(2):187-94 [16490846.001]
  • [Cites] Dermatol Surg. 2005 Nov;31(11 Pt 1):1428-33 [16416612.001]
  • [Cites] Dermatol Surg. 2005 Sep;31(9 Pt 1):1094-9; discussion 1100 [16164856.001]
  • [Cites] Curr Surg. 2005 Sep-Oct;62(5):518-26 [16125611.001]
  • [Cites] Arch Facial Plast Surg. 2005 Sep-Oct;7(5):342-6 [16172346.001]
  • [Cites] J Craniofac Surg. 2005 May;16(3):439-43 [15915111.001]
  • [Cites] Dermatol Surg. 2005 Jan;31(1):10-5 [15720088.001]
  • [Cites] Dermatol Surg. 2004 Dec;30(12 Pt 1):1479-85 [15606735.001]
  • [Cites] Lancet. 2004 Nov 13-19;364(9447):1766-72 [15541449.001]
  • [Cites] Am J Otolaryngol. 2004 Nov-Dec;25(6):385-93 [15547806.001]
  • [Cites] J Am Acad Dermatol. 1998 Nov;39(5 Pt 1):698-703 [9810885.001]
  • [Cites] Semin Cutan Med Surg. 1998 Jun;17(2):80-95 [9669602.001]
  • [Cites] J Am Acad Dermatol. 1998 Jul;39(1):79-97 [9674401.001]
  • [Cites] Dermatol Surg. 1997 Nov;23(11):1061-6 [9391565.001]
  • [Cites] Dermatol Surg. 1997 Oct;23(10):929-33 [9357504.001]
  • [Cites] Dermatol Surg. 1997 Feb;23(2):105-10 [9107284.001]
  • [Cites] J Am Acad Dermatol. 1995 Jul;33(1):1-15; quiz 16-8 [7601925.001]
  • (PMID = 20567701.001).
  • [ISSN] 1536-0067
  • [Journal-full-title] Seminars in plastic surgery
  • [ISO-abbreviation] Semin Plast Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2884874
  • [Keywords] NOTNLM ; Mohs micrographic surgery / cutaneous oncology / skin cancer
  •  go-up   go-down


49. Filip A, Clichici S, Daicoviciu D, Adriana M, Postescu ID, Perde-Schrepler M, Olteanu D: Photochemoprevention of cutaneous neoplasia through natural products. Exp Oncol; 2009 Mar;31(1):9-15
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Non-melanoma skin cancers such as squamous cell carcinoma and basal cell carcinoma are the most common types of human tumors, representing 30% of the new cases of malignancies diagnosed each year.
  • Ultraviolet radiation (UV) from the sun is a major cause of non-melanoma skin cancer in humans.
  • Here we review the progress in the research of new and existing agents developed to protect the skin exposed to UV.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Cat's Claw. Flavonoids / therapeutic use. Phenols / therapeutic use. Phytotherapy. Polypodium. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19300410.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Flavonoids; 0 / Phenols; 0 / Plant Preparations; 0 / Polyphenols; 0 / Silymarin; 4RKY41TBTF / silybin
  • [Number-of-references] 62
  •  go-up   go-down


50. Stoebner PE, Le Gallic L, Berthe ML, Boulle N, Lallemant B, Marque M, Gaspard C, Delfour C, Lavabre-Bertrand T, Martinez J, Meunier L: Decreased expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in basal cell carcinomas. Exp Dermatol; 2008 Nov;17(11):908-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in basal cell carcinomas.
  • Thymidine phosphorylase (TP)/platelet-derived endothelial cell growth factor is associated with tumor angiogenesis.
  • We evaluated the TP mRNA and protein expression in basal cell carcinomas (BCC) and in various skin tumors including numerous BCC histological simulants.
  • Immunohistochemistry was performed on 99 paraffin sections of formalin-fixed skin tumors using monoclonal antibodies (mAb) against TP.
  • TP mRNA levels were measured by real time RT-PCR in whole BCCs (wBCC) and laser capture microdissected (LCM) BCC tumor cells.
  • TP immunostaining was negative in all BCC variants and in most of the benign trichogeneic tumors studied.
  • By contrast, TP was constantly immunodetected in actinic keratosis (AK), squamous cell carcinomas (SCC), syringomatous carcinomas (SC), basosquamous carcinomas (BSC) and melanomas.
  • TP mRNA levels were low and statistically not different in wBCC and normal skin but were strongly downregulated in LCM-BCC as compared with LCM-normal epidermis.
  • We concluded that (i) anti-TP mAb is an useful marker to differentiate BCC from AK, SCC, BSC and SC but not from trichoblastic tumors, (ii) the lack of TP protein expression in BCC tumoral cells is linked to transcriptional regulatory mechanisms, (iii) the low TP mRNA levels in whole BCC may be related to the low intra-tumoral microvessel density, the slow growth and the very low metastatic potential of these tumors.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology. Thymidine Phosphorylase / genetics
  • [MeSH-minor] Carcinoma, Basosquamous / genetics. Carcinoma, Basosquamous / metabolism. Carcinoma, Basosquamous / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Down-Regulation. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Keratosis, Actinic / genetics. Keratosis, Actinic / metabolism. Keratosis, Actinic / pathology. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18341568.001).
  • [ISSN] 1600-0625
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.4.2.4 / Thymidine Phosphorylase
  •  go-up   go-down


51. Basile J, Thiers B, Maize J Sr, Lathers DM: Chemokine receptor expression in non-melanoma skin cancer. J Cutan Pathol; 2008 Jul;35(7):623-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemokine receptor expression in non-melanoma skin cancer.
  • Prior studies have shown that in metastatic melanoma and squamous cell carcinoma of the head and neck upregulation of CXC (alpha) chemokine receptor (CXCR)4 and CC (beta) chemokine receptor (CCR)7 expression is accompanied by downregulation of the chemokine receptor CCR6.
  • However, the expression patterns of CCR6, CCR7 and CXCR4 in non-melanoma skin cancer have yet to be elucidated.
  • METHODS: The expression patterns of CCR6, CCR7 and CXCR4 were determined using an immunohistochemical approach on formalin-fixed, paraffin-embedded normal, pre-cancerous actinic (solar) keratosis, squamous cell carcinoma and basal cell carcinoma tissues.
  • RESULTS: Analysis of chemokine receptor expression showed downregulation of CCR6 and upregulation of CCR7 and CXCR4 in potentially metastatic non-melanoma skin cancer, invasive squamous cell carcinoma, but this pattern did not exist in non-melanoma skin cancer with no metastatic potential, basal cell carcinoma; or actinic keratosis, when compared with normal skin.
  • CONCLUSIONS: Chemokine receptor expression may influence the biological behavior of non-melanoma skin cancer.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Keratosis / metabolism. Receptors, CCR6 / metabolism. Receptors, CCR7 / metabolism. Receptors, CXCR4 / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Analysis of Variance. Biomarkers / metabolism. Down-Regulation. Humans. Immunohistochemistry. Neoplasm Metastasis / physiopathology. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Skin / metabolism. Skin / pathology. Staining and Labeling. Ultraviolet Rays / adverse effects. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18312436.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CCR6 protein, human; 0 / CCR7 protein, human; 0 / CXCR4 protein, human; 0 / Receptors, CCR6; 0 / Receptors, CCR7; 0 / Receptors, CXCR4
  •  go-up   go-down


52. Quatresooz P, Piérard GE, Paquet P, Blaise G, Piérard-Franchimont C: [Cutaneous cancers after organ transplantation]. Rev Med Liege; 2007 Nov;62(11):663-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Cancers cutanés après transplantation d'organe, un revers de médaille.
  • Cutaneous carcinomas are the most frequent malignancies developing after organ transplantation.
  • The usual squamous to basal cell carcinoma ratio is increased and reversed compared to the general population.
  • Carcinomas primarily result from the combination of cumulative sun exposure, fair skin phototype and effects of immunosuppressive drugs.
  • The severity of these carcinomas is due to their multiplicity and to the occurrence of more aggressive lesions.
  • The treatment of the neoplastic lesions is based on their early and complete excision with histological control of the nature of the neoplasm, the safety surgical margins, and the determination of prognostic factors.
  • [MeSH-major] Immunosuppression / adverse effects. Immunosuppressive Agents / adverse effects. Organ Transplantation. Skin Neoplasms / etiology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18217642.001).
  • [ISSN] 0370-629X
  • [Journal-full-title] Revue médicale de Liège
  • [ISO-abbreviation] Rev Med Liege
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  • [Number-of-references] 43
  •  go-up   go-down


53. Okuyama R, Tagami H, Aiba S: Notch signaling: its role in epidermal homeostasis and in the pathogenesis of skin diseases. J Dermatol Sci; 2008 Mar;49(3):187-94
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Notch signaling: its role in epidermal homeostasis and in the pathogenesis of skin diseases.
  • Skin undergoes self-renewal throughout life.
  • Terminally differentiated keratinocytes, namely the corneocytes, are continually shed from the surface of the skin, whereas immature cells produce progeny that proceed through the differentiation process.
  • Notch signaling controls a number of cellular processes including cell fate decision, proliferation, differentiation and survival/apoptosis.
  • Hence, Notch and its ligands are expressed in multiple tissues including the skin, where they are abundantly expressed in the epidermis.
  • Notch activation results in the promotion of growth arrest and the onset of differentiation, therefore suggesting that specific Notch activation may regulate skin homeostasis by balancing these processes, i.e.
  • Notch signaling functions as a molecular switch that controls the transition of cells between skin layers during the epidermal differentiation process.
  • Recent advances in the study of Notch signaling have confirmed that there is cross-talk between the Notch signaling pathway and a variety of other signaling molecules including Sonic hedgehog (Shh), beta-catenin and the p53 family member, p63.
  • In addition, Notch counteracts the action of p63 to maintain immature cell characteristics.
  • However, aberrant Notch signaling results in the development of psoriasis and skin cancers such as squamous cell carcinoma, basal cell carcinoma and malignant melanoma.
  • Future efforts to further define how Notch controls cell proliferation and differentiation may lead to the application of Notch in new therapies for various skin diseases.
  • [MeSH-major] Receptors, Notch / physiology. Signal Transduction / physiology. Skin / cytology. Skin Diseases / etiology
  • [MeSH-minor] Animals. Cell Differentiation. Cell Proliferation. Homeostasis. Humans. Langerhans Cells / physiology. Melanocytes / physiology

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17624739.001).
  • [ISSN] 0923-1811
  • [Journal-full-title] Journal of dermatological science
  • [ISO-abbreviation] J. Dermatol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Receptors, Notch
  • [Number-of-references] 67
  •  go-up   go-down


54. Srikanth V, Fryer J, Venn A, Blizzard L, Newman L, Cooley H, Albion T, Jones G: The association between non-melanoma skin cancer and osteoporotic fractures--a population-based record linkage study. Osteoporos Int; 2007 May;18(5):687-92
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The association between non-melanoma skin cancer and osteoporotic fractures--a population-based record linkage study.
  • We studied the association between osteoporotic fractures and prior non-melanoma skin cancer (NMSC, a biomarker for cumulative sun exposure).
  • We aimed to study the association between non-melanoma skin cancer (NMSC), a marker of cumulative sun exposure, and osteoporotic fractures in an older cohort.
  • This effect was significant for most fracture subtypes except pelvic and wrist fractures and observed for both NMSC subtypes, squamous cell carcinoma and basal cell carcinoma.
  • Achieving a balance between adequate lifetime sun exposure and protection against its adverse effects (such as fractures and skin cancer) may require assessment of individual risks.
  • [MeSH-major] Fractures, Bone / etiology. Medical Record Linkage. Osteoporosis / complications. Skin Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Fractures.
  • MedlinePlus Health Information. consumer health - Osteoporosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2005 May 7-13;365(9471):1621-8 [15885294.001]
  • [Cites] Am J Epidemiol. 1990 Feb;131(2):373-5 [2296988.001]
  • [Cites] J Epidemiol Community Health. 2004 Feb;58(2):142-4 [14729897.001]
  • [Cites] Osteoporos Int. 2005 Jun;16(6):636-41 [15448989.001]
  • [Cites] Am J Clin Nutr. 1995 Mar;61(3 Suppl):638S-645S [7879731.001]
  • [Cites] Public Health Nutr. 2001 Apr;4(2B):547-59 [11683549.001]
  • [Cites] Am J Clin Nutr. 1990 Jun;51(6):1075-81 [2349922.001]
  • [Cites] Osteoporos Int. 2001;12(2):124-30 [11303712.001]
  • [Cites] J Bone Miner Res. 1995 Nov;10(11):1802-15 [8592959.001]
  • [Cites] Osteoporos Int. 2005 Nov;16(11):1425-31 [15744449.001]
  • [Cites] Value Health. 2003 Sep-Oct;6(5):574-83 [14627064.001]
  • [Cites] Cancer Causes Control. 1997 May;8(3):271-83 [9498892.001]
  • [Cites] J Invest Dermatol. 2003 Jun;120(6):1087-93 [12787139.001]
  • [Cites] Aust N Z J Med. 2000 Apr;30(2):209-14 [10833112.001]
  • [Cites] J Clin Endocrinol Metab. 1999 May;84(5):1562-6 [10323380.001]
  • [Cites] Bone Miner. 1994 May;25(2):83-92 [8086854.001]
  • [Cites] N Engl J Med. 1992 Dec 3;327(23 ):1637-42 [1331788.001]
  • [Cites] BMJ. 2005 Apr 30;330(7498):1003 [15860827.001]
  • [Cites] Australas J Dermatol. 1997 Jun;38 Suppl 1:S1-6 [10994463.001]
  • [Cites] J Am Coll Nutr. 2003 Apr;22(2):142-6 [12672710.001]
  • [Cites] Eur J Clin Nutr. 2004 Aug;58(8):1095-109 [15054436.001]
  • [Cites] Eur J Clin Nutr. 1999 Oct;53(10):824-9 [10556991.001]
  • [Cites] Osteoporos Int. 2005 Mar;16 Suppl 2:S3-7 [15365697.001]
  • [Cites] Am J Clin Nutr. 2004 Dec;80(6):1645-9 [15585781.001]
  • [Cites] Osteoporos Int. 1999;9(1):45-54 [10367029.001]
  • [Cites] Am J Epidemiol. 2002 Apr 1;155(7):614-21 [11914188.001]
  • [Cites] BMJ. 2003 Aug 9;327(7410):316 [12907484.001]
  • [Cites] Am J Clin Nutr. 1987 Dec;46(6):1005-10 [3687818.001]
  • (PMID = 17211531.001).
  • [ISSN] 0937-941X
  • [Journal-full-title] Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
  • [ISO-abbreviation] Osteoporos Int
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


55. Anderegg U, Breitschwerdt K, Köhler MJ, Sticherling M, Haustein UF, Simon JC, Saalbach A: MEL4B3, a novel mRNA is induced in skin tumors and regulated by TGF-beta and pro-inflammatory cytokines. Exp Dermatol; 2005 Sep;14(9):709-18
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MEL4B3, a novel mRNA is induced in skin tumors and regulated by TGF-beta and pro-inflammatory cytokines.
  • Tumor-stroma interactions play a decisive role in the growth and metastasis of solid tumors, and involve signalling either by soluble mediators or direct cell-cell interaction.
  • Here, we report the isolation and characterisation of a novel cDNA (MEL4B3), which is induced in cultured dermal fibroblasts exposed to supernatants of melanoma cell lines.
  • In situ hybridisation revealed the expression of MEL4B3 in malignant melanoma increasing with tumor depth; in basal cell carcinoma and in squamous cell carcinoma.
  • MEL4B3 was barely detectable in normal skin or non-malignant melanocytic naevi.
  • Furthermore, MEL4B3 was expressed at high level in the epidermis of psoriatic skin.
  • In vitro, the expression of MEL4B3 was found to be induced by the exposure of human dermal fibroblasts to melanoma cell culture supernatants or to transforming growth factor-beta, interleukin-1 and tumor necrosis factor-alpha.
  • The expression MEL4B3 therefore reflects closely cell activation occurring during tumor growth, metastasis and inflammation.
  • [MeSH-major] Neoplasm Proteins / biosynthesis. RNA, Messenger / metabolism. Skin Neoplasms / metabolism. Transforming Growth Factor beta / metabolism
  • [MeSH-minor] Amino Acid Sequence. Base Sequence. Blotting, Northern. Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Cells, Cultured. Culture Media / metabolism. Culture Media / pharmacology. Culture Media, Conditioned / pharmacology. Cytokines / metabolism. DNA, Complementary / metabolism. Fibroblasts / metabolism. Flow Cytometry. Gene Expression Regulation, Neoplastic. Humans. In Situ Hybridization. Inflammation. Keratinocytes / metabolism. Microcirculation. Molecular Sequence Data. Neoplasm Metastasis. Polymerase Chain Reaction. RNA, Complementary / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Skin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16098131.001).
  • [ISSN] 0906-6705
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Culture Media; 0 / Culture Media, Conditioned; 0 / Cytokines; 0 / DNA, Complementary; 0 / FNDC1 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Complementary; 0 / RNA, Messenger; 0 / Transforming Growth Factor beta
  •  go-up   go-down


56. Malejczyk M, Józwiak J, Jablonska S, Pfister H, Majewski S, Malejczyk J: Circulating soluble tumour necrosis factor receptors in patients with epidermodysplasia verruciformis as compared to patients with cutaneous tumours in the general population. Oncol Rep; 2005 Jan;13(1):151-5
Genetic Alliance. consumer health - Epidermodysplasia Verruciformis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Soluble tumour necrosis factor receptors type I and II (sTNF-RI and II) were evaluated in sera from patients with epidermodysplasia verruciformis and patients with cutaneous warts, actinic keratoses, squamous cell carcinomas or basal cell carcinomas by specific enzyme-linked immunobiological assays.
  • The levels of sTNF-RI were significantly increased in patients with multiple actinic keratoses, squamous cell carcinoma and basal cell carcinoma.
  • [MeSH-major] Epidermodysplasia Verruciformis / diagnosis. Receptors, Tumor Necrosis Factor, Type I / blood. Receptors, Tumor Necrosis Factor, Type II / blood
  • [MeSH-minor] Adult. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Skin Neoplasms / diagnosis. Skin Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15583817.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Receptors, Tumor Necrosis Factor, Type I; 0 / Receptors, Tumor Necrosis Factor, Type II
  •  go-up   go-down


57. Ishihara K, Saida T, Otsuka F, Yamazaki N, Prognosis and Statistical Investigation Committee of the Japanese Skin Cancer Society: Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update. Int J Clin Oncol; 2008 Feb;13(1):33-41
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update.
  • BACKGROUND: In the previous report of the Prognosis and Statistical Investigation Committee of the Japanese Skin Cancer Society, we tabulated data on patients with malignant melanoma who had been registered at major medical institutions (22 institutions on average) in Japan over 5-year periods from 1987 to 1991 (group A) and from 1992 to 1996 (group B).
  • In the present study, patients registered from 1997 to 2001 (group C) were investigated and the data were compared with findings obtained by the subsequent follow-up of groups A and B.
  • Because the International Union Against Cancer (UICC) TNM and stage classifications for malignant melanoma were changed substantially in 2002, analyses in the present investigation were performed according to the new classifications.
  • In addition, the numbers of patients with various kinds of skin malignancies, including not only malignant melanoma but also basal cell carcinoma, squamous cell carcinoma, mycosis fungoides, actinic keratosis, Bowen's disease, and Paget's disease, registered at approximately 100 medical institutions in Japan from 1987 to 2001, were also investigated and data were tabulated.
  • RESULTS: The nationwide survey of Japanese patients with malignant skin tumors from 1987 to 2001 showed that the most prevalent skin tumor was basal cell carcinoma, which increased year by year, followed by squamous cell carcinoma, and then by malignant melanoma.
  • The following results were obtained from the data for melanoma patients registered at major institutions from 1987 to 2001. (1) The overall 10-year survival rates for melanoma patients in each chronological group were ranked as: group C > B > A, although only the difference between groups C and A was statistically significant. (2) The male-to-female ratio ranged from 1: 0.97 to 1: 1.14, and the survival rate of female patients was higher than that of male patients (the 140-month survival rate was 70.6% in females and 60% in males). (3) Assessment of the age distribution showed that the number of patients increased rapidly from ages 40-49 years and reached a peak at around 60 years in all three groups. (4) The sole of the foot was the most common site of melanoma in both males and females, while melanomas on the lower limbs were also prevalent in females. (5) Acral lentiginous melanoma (ALM) was the most common type in all three groups, accounting for nearly 50% of the patients in each group.
  • The prognosis of NM was the worst, while that of SSM was the most favorable. (6) The proportion of stage I patients was larger in group C than in groups A and B, but no significant difference among the groups was observed in the proportions of stage II, III, and IV patients.
  • For patients in stage IV, the survival rate in group C was slightly lower than that in group A or B. (7) In group C, the overall survival rates for substages III A, B, and C were ranked as III A > III B > III C. (8) The overall survival rates for stage IV M1a, M1b, and M1c were ranked as M1a > M1b > M1c.
  • CONCLUSION: In Japan, the number of patients with malignant skin tumors has increased year by year.
  • The prognosis of patients with advanced malignant melanoma remains extremely poor, but that of patients in stage III has shown an improvement.
  • [MeSH-major] Melanoma / epidemiology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Epidemiol. 1995 Oct;24(5):897-907 [8557445.001]
  • [Cites] Int J Clin Oncol. 2003 Jun;8(3):139-50 [12851837.001]
  • [Cites] Int J Clin Oncol. 2001 Jun;6(3):109-16 [11706778.001]
  • [Cites] Cancer. 2000 Mar 15;88(6):1484-91 [10717634.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3635-48 [11504745.001]
  • [Cites] Harefuah. 1995 Jun 15;128(12):745-51, 824 [7557679.001]
  • (PMID = 18307017.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


58. Hong H, Sun J, Cai W: Anatomical and molecular imaging of skin cancer. Clin Cosmet Investig Dermatol; 2008;1:1-17

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anatomical and molecular imaging of skin cancer.
  • Skin cancer is the most common form of cancer types.
  • It is generally divided into two categories: melanoma (∼ 5%) and nonmelanoma (∼ 95%), which can be further categorized into basal cell carcinoma, squamous cell carcinoma, and some rare skin cancer types.
  • Biopsy is still the gold standard for skin cancer evaluation in the clinic.
  • Various anatomical imaging techniques have been used to evaluate different types of skin cancer lesions, including laser scanning confocal microscopy, optical coherence tomography, high-frequency ultrasound, terahertz pulsed imaging, magnetic resonance imaging, and some other recently developed techniques such as photoacoustic microscopy.
  • However, anatomical imaging alone may not be sufficient in guiding skin cancer diagnosis and therapy.
  • Over the last decade, various molecular imaging techniques (in particular single photon emission computed tomography and positron emission tomography) have been investigated for skin cancer imaging.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Z Arztl Fortbild Qualitatssich. 1997 Jul;91(4):347-53 [9340205.001]
  • [Cites] Radiographics. 1997 Nov-Dec;17(6):1559-65 [9397463.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1770-6 [9586890.001]
  • [Cites] NMR Biomed. 2008 Mar;21(3):296-300 [18246539.001]
  • [Cites] J Biomed Opt. 2008 Jan-Feb;13(1):014003 [18315361.001]
  • [Cites] Adv Exp Med Biol. 2008;624:215-26 [18348459.001]
  • [Cites] Adv Exp Med Biol. 2008;624:227-40 [18348460.001]
  • [Cites] Adv Exp Med Biol. 2008;624:296-318 [18348465.001]
  • [Cites] J Biomed Opt. 2008 Mar-Apr;13(2):024013 [18465976.001]
  • [Cites] J Nucl Med. 2008 Jun;49 Suppl 2:113S-28S [18523069.001]
  • [Cites] Opt Express. 2002 Jul 29;10(15):707-13 [19451924.001]
  • [Cites] Biotechniques. 2005 Dec;39(6 Suppl):S6-13 [20158503.001]
  • [Cites] J Nucl Med. 1990 Nov;31(11):1831-5 [2230996.001]
  • [Cites] Ann Surg. 1986 Sep;204(3):223-35 [3753057.001]
  • [Cites] Science. 1994 Apr 22;264(5158):569-71 [7512751.001]
  • [Cites] Annu Rev Cell Dev Biol. 1996;12:697-715 [8970741.001]
  • [Cites] Dermatol Surg. 1997 Jan;23(1):43-5 [9107293.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):12814-8 [9788997.001]
  • [Cites] Am J Pathol. 1998 Nov;153(5):1347-51 [9811323.001]
  • [Cites] AJR Am J Roentgenol. 1999 Feb;172(2):457-61 [9930803.001]
  • [Cites] Nucl Med Biol. 1999 Aug;26(6):687-93 [10587108.001]
  • [Cites] Crit Rev Oncog. 2000;11(2):147-63 [11005510.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5649-58 [11059756.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4474-82 [11389078.001]
  • [Cites] Nucl Med Biol. 2001 Jul;28(5):493-8 [11516693.001]
  • [Cites] J Nucl Med. 2001 Dec;42(12):1847-55 [11752084.001]
  • [Cites] Nucl Med Biol. 2006 Aug;33(6):723-33 [16934691.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):913-21 [17146742.001]
  • [Cites] Br J Dermatol. 2007 Jan;156(1):81-4 [17199571.001]
  • [Cites] J Nucl Med. 2007 Jan;48(1):64-72 [17204700.001]
  • [Cites] J Nucl Med. 2007 Jan;48(1):73-80 [17204701.001]
  • [Cites] Cancer Imaging. 2006;6:204-8 [17208677.001]
  • [Cites] Bull Cancer. 2007 Jan;94(1):93-8 [17237009.001]
  • [Cites] J Nucl Med. 2007 Feb;48(2):304-10 [17268029.001]
  • [Cites] J Nucl Med. 2007 Mar;48(3):429-36 [17332621.001]
  • [Cites] Bioconjug Chem. 2007 May-Jun;18(3):765-72 [17348700.001]
  • [Cites] Dermatol Surg. 2007 Apr;33(4):421-5; discussion 425-6 [17430375.001]
  • [Cites] Front Biosci. 2007;12:4514-24 [17485393.001]
  • [Cites] Rofo. 2007 Jun;179(6):618-26 [17492539.001]
  • [Cites] Nucl Med Biol. 2007 May;34(4):363-70 [17499725.001]
  • [Cites] J Nucl Med. 2007 Jun;48(6):987-94 [17504880.001]
  • [Cites] Surg Oncol Clin N Am. 2007 Apr;16(2):403-30 [17560520.001]
  • [Cites] J Am Acad Dermatol. 2007 Oct;57(4):629-37 [17610989.001]
  • [Cites] J Biomed Opt. 2007 May-Jun;12(3):034027 [17614735.001]
  • [Cites] Arch Dermatol. 2007 Jul;143(7):883-6 [17638732.001]
  • [Cites] Cancer Biother Radiopharm. 2007 Jun;22(3):333-41 [17651039.001]
  • [Cites] Cutis. 2007 Mar;79(3):241-8 [17674590.001]
  • [Cites] Dermatol Surg. 2007 Oct;33(10):1158-74 [17903149.001]
  • [Cites] Dermatol Surg. 2007 Oct;33(10):1220-7; discussion 1226-7 [17903155.001]
  • [Cites] J Radiol. 1998 Apr;79(4):313-7 [9757255.001]
  • [Cites] Eur J Nucl Med. 1998 Oct;25(10):1383-9 [9818277.001]
  • [Cites] Bioconjug Chem. 2006 May-Jun;17(3):662-9 [16704203.001]
  • [Cites] J Dermatol Sci. 2006 Aug;43(2):135-41 [16806842.001]
  • [Cites] J Am Acad Dermatol. 2006 Sep;55(3):408-12 [16908344.001]
  • [Cites] J Nucl Med. 1999 Apr;40(4):591-603 [10210218.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2917-23 [10383155.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;44(4):343-8 [10447583.001]
  • [Cites] J Nucl Med. 1999 Jun;40(6):1061-71 [10452325.001]
  • [Cites] J Am Acad Dermatol. 2000 Jul;43(1 Pt 1):42-8 [10863222.001]
  • [Cites] Neoplasia. 2000 Jan-Apr;2(1-2):9-25 [10933065.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1781-5 [11280722.001]
  • [Cites] J Clin Oncol. 2001 May 15;19(10):2674-8 [11352959.001]
  • [Cites] J Nucl Med. 2001 May;42(5 Suppl):1S-93S [11483694.001]
  • [Cites] Science. 2001 Oct 12;294(5541):339-45 [11546839.001]
  • [Cites] Hybrid Hybridomics. 2001;20(5-6):351-60 [11839253.001]
  • [Cites] Genes Dev. 2003 Mar 1;17(5):545-80 [12629038.001]
  • [Cites] Nat Rev Cancer. 2002 Feb;2(2):91-100 [12635172.001]
  • [Cites] Pigment Cell Res. 2003 Jun;16(3):266-72 [12753400.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3172-9 [12789293.001]
  • [Cites] Lab Invest. 2003 Sep;83(9):1279-83 [13679435.001]
  • [Cites] Nat Biotechnol. 2003 Nov;21(11):1361-7 [14595364.001]
  • [Cites] Bioconjug Chem. 2003 Nov-Dec;14(6):1177-84 [14624632.001]
  • [Cites] Bioconjug Chem. 2004 Jan-Feb;15(1):61-9 [14733584.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1411-8 [14973076.001]
  • [Cites] Magn Reson Imaging. 2004 Jul;22(6):843-50 [15234453.001]
  • [Cites] Mod Pathol. 2005 Apr;18(4):469-74 [15529179.001]
  • [Cites] J Nucl Med. 2005 Jan;46(1):121-9 [15632042.001]
  • [Cites] Skin Res Technol. 2007 Nov;13(4):463-71 [17908200.001]
  • [Cites] Dermatology. 2007;215(4):365-72 [17912001.001]
  • [Cites] Panminerva Med. 2007 Sep;49(3):119-38 [17912148.001]
  • [Cites] Nucl Med Biol. 2007 Nov;34(8):945-53 [17998097.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Dec;7(12):1707-16 [18062745.001]
  • [Cites] Int J Pharm. 2008 Apr 2;353(1-2):233-42 [18191509.001]
  • [Cites] Bioconjug Chem. 2008 Feb;19(2):539-47 [18197608.001]
  • [Cites] Skin Res Technol. 2008 Feb;14(1):18-25 [18211598.001]
  • [Cites] Skin Res Technol. 2008 Feb;14(1):89-92 [18211606.001]
  • [Cites] Br J Dermatol. 2008 Feb;158(2):329-33 [18215250.001]
  • [Cites] Dermatol Surg. 2008 May;34(5):610-9 [18261097.001]
  • [Cites] Anal Sci. 2008 Feb;24(2):185-92 [18270407.001]
  • [Cites] Curr Opin Oncol. 2008 Mar;20(2):196-200 [18300770.001]
  • [Cites] Int J Cosmet Sci. 2008 Feb;30(1):1-17 [18377626.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2008 May;22(5):606-15 [18410618.001]
  • [Cites] J Nucl Med. 2008 May;49(5):823-9 [18413404.001]
  • [Cites] Clin Nucl Med. 2008 May;33(5):353-5 [18431156.001]
  • [Cites] J Nucl Med. 2008 Jun;49(6):879-86 [18483090.001]
  • [Cites] Semin Cutan Med Surg. 2008 Mar;27(1):37-43 [18486023.001]
  • [Cites] AJR Am J Roentgenol. 2008 Jul;191(1):285-9 [18562760.001]
  • [Cites] Cancer Res. 1990 Feb 1;50(3 Suppl):904s-908s [2297740.001]
  • [Cites] Cancer Res. 1990 Feb 1;50(3 Suppl):941s-948s [2297746.001]
  • [Cites] Cancer Res. 1990 Jun 1;50(11):3445-52 [2334941.001]
  • [Cites] Neoplasma. 1989;36(5):505-11 [2812147.001]
  • [Cites] J Nucl Med. 1988 Mar;29(3):329-37 [3346743.001]
  • [Cites] Biomed Pharmacother. 1986;40(10):392-8 [3580508.001]
  • [Cites] Cancer Immunol Immunother. 1987;24(3):221-4 [3594484.001]
  • [Cites] NCI Monogr. 1987;(3):3-9 [3821916.001]
  • [Cites] Radiology. 1985 May;155(2):487-92 [3983400.001]
  • [Cites] Cancer Res. 1985 Jul;45(7):3378-87 [4005860.001]
  • [Cites] Br J Urol. 1994 Oct;74(4):521-2 [7820438.001]
  • [Cites] Arch Dermatol. 1995 Mar;131(3):279-85 [7887656.001]
  • [Cites] Int J Cancer. 1994 Sep 1;58(5):749-55 [8077062.001]
  • [Cites] Melanoma Res. 1993 Dec;3(6):395-401 [8161879.001]
  • [Cites] Br J Dermatol. 1993 May;128(5):525-32 [8504043.001]
  • [Cites] Clin Nucl Med. 1997 Jan;22(1):25-9 [8993869.001]
  • [Cites] Nucl Med Biol. 1997 Feb;24(2):171-8 [9089709.001]
  • [Cites] Bioconjug Chem. 1997 May-Jun;8(3):347-53 [9177840.001]
  • [Cites] Magn Reson Med. 2005 Mar;53(3):621-7 [15723405.001]
  • [Cites] PLoS Med. 2005 Mar;2(3):e70 [15783258.001]
  • [Cites] Mol Imaging. 2004 Oct;3(4):343-51 [15802051.001]
  • [Cites] J Med Chem. 2005 Apr 21;48(8):2985-92 [15828837.001]
  • [Cites] J Nucl Med. 2005 Aug;46(8):1333-41 [16085591.001]
  • [Cites] Nat Med. 2005 Nov;11(11):1250-5 [16258537.001]
  • [Cites] Mod Pathol. 2006 Feb;19 Suppl 2:S127-47 [16446711.001]
  • [Cites] J Am Acad Dermatol. 2006 Apr;54(4):638-43 [16546585.001]
  • [Cites] J Nucl Med. 2006 May;47(5):763-9 [16644745.001]
  • [Cites] J Nucl Med. 2006 Jun;47(6):957-67 [16741305.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3942-9 [16818691.001]
  • [Cites] Nat Biotechnol. 2006 Jul;24(7):848-51 [16823374.001]
  • [Cites] J Nucl Med. 2006 Sep;47(9):1434-9 [16954550.001]
  • [Cites] Mol Cancer Ther. 2006 Nov;5(11):2624-33 [17121909.001]
  • [Cites] J Dermatol Sci. 2007 Mar;45(3):167-73 [17215110.001]
  • [Cites] Conf Proc IEEE Eng Med Biol Soc. 2005;1:190-2 [17282143.001]
  • [Cites] Melanoma Res. 2007 Apr;17(2):117-27 [17496787.001]
  • [Cites] Tech Vasc Interv Radiol. 2006 Sep;9(3):125-32 [17561215.001]
  • [Cites] Arch Dermatol. 2007 Jun;143(6):727-34 [17576938.001]
  • [Cites] J Dtsch Dermatol Ges. 2007 Aug;5(8):689-707 [17659044.001]
  • [Cites] Int J Dermatol. 2007 Sep;46(9):895-904 [17822489.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):186-208 [17846765.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17489-93 [17954911.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Nov;7(11):1633-42 [18020929.001]
  • [Cites] Br J Dermatol. 2007 Dec;157 Suppl 2:56-8 [18067634.001]
  • [Cites] Mol Cancer Ther. 2008 Jan;7(1):101-9 [18202013.001]
  • [Cites] Cancer. 2002 Feb 15;94(4 Suppl):1196-201 [11877745.001]
  • [Cites] Phys Med Biol. 2002 Apr 7;47(7):R67-84 [11996068.001]
  • [Cites] J Med Chem. 2002 Jul 4;45(14):3048-56 [12086490.001]
  • [Cites] Ann Surg Oncol. 2002 Aug;9(7):646-53 [12167578.001]
  • [Cites] Phys Med Biol. 2002 Nov 7;47(21):3847-52 [12452576.001]
  • [Cites] J Nucl Med. 2002 Dec;43(12):1699-706 [12468522.001]
  • [Cites] J Invest Dermatol. 2003 Jan;120(1):72-8 [12535200.001]
  • [Cites] J Nucl Med. 2003 Aug;44(8):1210-8 [12902409.001]
  • [Cites] Cancer Res. 1992 May 1;52(9):2545-8 [1314697.001]
  • [Cites] Science. 1992 Aug 28;257(5074):1248-51 [1325670.001]
  • [Cites] Br J Dermatol. 2003 Nov;149(5):1035-40 [14632811.001]
  • [Cites] Optometry. 2003 Dec;74(12):760-4 [14677727.001]
  • [Cites] Klin Monbl Augenheilkd. 2003 Dec;220(12):822-9 [14704937.001]
  • [Cites] J Nucl Med. 2004 Jan;45(1):116-23 [14734683.001]
  • [Cites] Nuklearmedizin. 2004 Feb;43(1):26-32 [14978538.001]
  • [Cites] Br J Dermatol. 2004 Apr;150(4):677-86 [15099363.001]
  • [Cites] Ann Surg Oncol. 2004 Aug;11(8):731-8 [15249335.001]
  • [Cites] J Nucl Med. 2004 Aug;45(8):1323-7 [15299056.001]
  • [Cites] J Invest Dermatol. 2004 Sep;123(3):458-63 [15304083.001]
  • [Cites] Br J Dermatol. 2004 Aug;151(2):424-32 [15327550.001]
  • [Cites] Cancer J. 2004 Jul-Aug;10(4):262-70 [15383207.001]
  • [Cites] Vestn Rentgenol Radiol. 2004 Mar-Apr;(2):44-54 [15458273.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 2004 Dec;20(6):283-8 [15533235.001]
  • [Cites] Phys Med Biol. 2004 Nov 7;49(21):N363-9 [15584535.001]
  • [Cites] Arch Dermatol. 2005 Feb;141(2):217-24 [15724019.001]
  • [Cites] Arch Dermatol. 2005 Feb;141(2):269-70 [15724029.001]
  • [Cites] Curr Opin Oncol. 2005 Mar;17(2):154-9 [15725921.001]
  • [Cites] J Nucl Med. 2005 May;46(5):887-95 [15872364.001]
  • [Cites] Curr Opin Oncol. 1992 Apr;4(2):380-5 [1591311.001]
  • [Cites] Nucl Med Biol. 2005 Jul;32(5):485-93 [15982579.001]
  • [Cites] Cancer Metastasis Rev. 2005 Jun;24(2):195-222 [15986132.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5616-21 [16061880.001]
  • [Cites] J Dermatol Sci. 2005 Nov;40(2):85-94 [16139481.001]
  • [Cites] Radiology. 1992 Aug;184(2):427-34 [1620841.001]
  • [Cites] J Biomed Opt. 2005 Sep-Oct;10(5):054010 [16292970.001]
  • [Cites] J Am Acad Dermatol. 2005 Dec;53(6):979-85 [16310058.001]
  • [Cites] Arch Dermatol. 2006 Mar;142(3):393; author reply 393 [16549724.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):193-200 [16615102.001]
  • (PMID = 21437135.001).
  • [ISSN] 1178-7015
  • [Journal-full-title] Clinical, cosmetic and investigational dermatology
  • [ISO-abbreviation] Clin Cosmet Investig Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3048596
  • [Keywords] NOTNLM ; anatomical imaging / antibody / melanoma / molecular imaging / positron emission tomography / skin cancer
  •  go-up   go-down


59. Reisinger DM, Shiffer JD, Cognetta AB Jr, Chang Y, Moore PS: Lack of evidence for basal or squamous cell carcinoma infection with Merkel cell polyomavirus in immunocompetent patients with Merkel cell carcinoma. J Am Acad Dermatol; 2010 Sep;63(3):400-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of evidence for basal or squamous cell carcinoma infection with Merkel cell polyomavirus in immunocompetent patients with Merkel cell carcinoma.
  • BACKGROUND: Merkel cell polyomavirus (MCV) was discovered by digital transcriptome subtraction as a monoclonal infection of Merkel cell carcinoma (MCC) tumors.
  • Polymerase chain reaction-based detection of the virus in other nonmelanoma skin cancers, however, has been inconsistent and controversial.
  • OBJECTIVE: We sought to directly assay for MCV infection in squamous cell carcinoma (SCC) or basal cell carcinoma (BCC) tumor cells by immunostaining for viral antigen.
  • METHODS: CM2B4, a monoclonal antibody to exon 2 peptides of MCV T antigen, was used to examine tumors from 20 patients with MCC with and without secondary SCC or BCC tumors.
  • RESULTS: MCV T antigen was readily detected in 15 (75%) of 20 MCC tumors including 11 MCC tumors from patients with secondary SCC or BCC.
  • In contrast to MCC, none of these secondary BCC or SCC was MCV T-antigen positive.
  • CONCLUSIONS: MCV T antigen is generally not expressed in BCC or SCC tumors from a population favored to have MCV infection, ie, those persons already given the diagnosis of MCV-positive MCC.
  • This suggests that episodic polymerase chain reaction detection of MCV genome in BCC or SCC tumors may represent coincidental rather than causal infection, and that these tumors share other noninfectious risk factors.
  • [MeSH-major] Carcinoma, Basal Cell / virology. Carcinoma, Merkel Cell / virology. Carcinoma, Squamous Cell / virology. Immunocompetence. Skin Neoplasms / virology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20584559.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA120726; United States / NCI NIH HHS / CA / CA136363
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Polyomavirus Transforming; 0 / DNA, Viral
  •  go-up   go-down


60. Yu L, Galan A, McNiff JM: Caveats in BerEP4 staining to differentiate basal and squamous cell carcinoma. J Cutan Pathol; 2009 Oct;36(10):1074-176
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caveats in BerEP4 staining to differentiate basal and squamous cell carcinoma.
  • BACKGROUND: Superficial skin biopsies of basal cell carcinoma (BCC) represent some of the most common dermatopathology specimens.
  • Superficial shave biopsies containing partial samples of lesions with squamatization present difficulties in distinguishing BCC from squamous cell carcinoma (SCC).
  • METHODS: We collected 12 cases of superficial biopsies of BCC with centrally located cords and strands suggesting squamous differentiation at the Yale Dermatopathology Laboratory over a 3-month period and stained them with BerEP4.
  • CONCLUSIONS: BerEP4 labeling is not reliable in superficial biopsies of BCC with squamoid features.
  • It is important to be aware of this caveat in interpreting BerEP4 staining for BCC and SCC.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Staining and Labeling

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 John Wiley & Sons A/S.
  • (PMID = 19187107.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / human epithelial antigen-125
  •  go-up   go-down


61. Asadi-Amoli F, Khoshnevis F, Haeri H, Jahanzad I, Pazira R, Shahsiah R: Comparative examination of androgen receptor reactivity for differential diagnosis of sebaceous carcinoma from squamous cell and basal cell carcinoma. Am J Clin Pathol; 2010 Jul;134(1):22-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative examination of androgen receptor reactivity for differential diagnosis of sebaceous carcinoma from squamous cell and basal cell carcinoma.
  • Sebaceous carcinoma (SEB) is the most important malignant tumor of the eyelid.
  • Early diagnosis and proper treatment significantly improve the outcome.
  • SEB should be differentiated histopathologically from basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).
  • In this study, the expression of androgen receptor (AR) in SEB, SCC, and BCC was evaluated.
  • Along with other markers and morphologic features, AR can be helpful in the diagnosis of SEB and its differentiation from SCC and BCC.
  • [MeSH-major] Adenocarcinoma, Sebaceous / diagnosis. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Eyelid Neoplasms / diagnosis. Receptors, Androgen / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Male

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20551262.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Androgen
  •  go-up   go-down


62. Kim GK, Del Rosso JQ, Bellew S: Skin cancer in asians: part 1: nonmelanoma skin cancer. J Clin Aesthet Dermatol; 2009 Aug;2(8):39-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin cancer in asians: part 1: nonmelanoma skin cancer.
  • Since the 1960s, basal cell carcinoma and squamous cell carcinoma among the Caucasian population have increased 3 to 8 percent annually.
  • Although Asians display relative protection from basal cell carcinoma and squamous cell carcinoma, incidence rates of these nonmelanoma skin cancers have been increasing over the past three decades.
  • With changing demographics and a steady rise in the minority population in the United States, there is an increased need for further studies of cutaneous malignancies within Asian and other ethnic populations.
  • This article reviews nonmelanoma skin cancers in the Asian population with an insight into contributing factors, such as skin type, occupation, cultural practices, and genetic components.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Photochem Photobiol. 2008 Jan-Feb;84(1):63-6 [18173702.001]
  • [Cites] Science. 1991 Jul 5;253(5015):49-53 [1905840.001]
  • [Cites] J Am Acad Dermatol. 2006 Nov;55(5):741-60; quiz 761-4 [17052479.001]
  • [Cites] Photochem Photobiol Sci. 2006 Feb;5(2):208-14 [16465307.001]
  • [Cites] Ann Surg. 1965 Feb;161:170-88 [14260013.001]
  • [Cites] Med Oncol. 1999 Jul;16(2):86-94 [10456656.001]
  • [Cites] Arch Dermatol. 1999 Jul;135(7):843-4 [10411160.001]
  • [Cites] J Am Acad Dermatol. 1990 Sep;23(3 Pt 1):413-21 [2212139.001]
  • [Cites] Arch Dermatol. 1988 Jun;124(6):869-71 [3377516.001]
  • [Cites] J Dermatol. 1984 Aug;11(4):313-21 [6392379.001]
  • [Cites] J Dermatol. 1990 Jun;17(6):342-6 [2384636.001]
  • [Cites] Plast Reconstr Surg. 1978 Sep;62(3):407-14 [693668.001]
  • [Cites] Ann Dermatol Venereol. 2003 Apr;130(4):413-6 [12843850.001]
  • [Cites] Br J Dermatol. 2001 Apr;144(4):841-8 [11298546.001]
  • [Cites] J Epidemiol. 1999 Dec;9(6 Suppl):S14-21 [10709346.001]
  • [Cites] Arch Dermatol. 1999 Jul;135(7):781-6 [10411152.001]
  • [Cites] J Dermatol Sci. 1999 Apr;19(3):161-5 [10215187.001]
  • [Cites] J Dermatol Sci. 1997 Nov;16(1):74-8 [9438911.001]
  • [Cites] J Dermatol Sci. 1997 Sep;15(3):183-7 [9302646.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 1996 Feb;12(1):22-6 [8884895.001]
  • [Cites] J Trauma. 1997 Jan;42(1):104-7 [9003266.001]
  • [Cites] Am J Dermatopathol. 2006 Dec;28(6):472-7 [17122490.001]
  • [Cites] J Surg Oncol. 1996 Feb;61(2):124-30 [8606543.001]
  • [Cites] Dermatol Surg. 1996 Mar;22(3):217-26 [8599733.001]
  • [Cites] Dermatol Clin. 1995 Jul;13(3):583-94 [7554506.001]
  • [Cites] J Invest Dermatol. 1994 Apr;102(4):440-4 [8151121.001]
  • [Cites] Recent Results Cancer Res. 1995;139:263-73 [7597297.001]
  • [Cites] Int J Cancer. 1993 Apr 1;53(6):886-91 [8473047.001]
  • [Cites] Am J Epidemiol. 1996 Dec 1;144(11):1034-40 [8942434.001]
  • (PMID = 20729955.001).
  • [ISSN] 1941-2789
  • [Journal-full-title] The Journal of clinical and aesthetic dermatology
  • [ISO-abbreviation] J Clin Aesthet Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2923966
  •  go-up   go-down


63. Bouwes Bavinck JN, Euvrard S, Naldi L, Nindl I, Proby CM, Neale R, Abeni D, Tessari GP, Feltkamp MC, Claudy A, Stockfleth E, Harwood CA, EPI-HPV-UV-CA group: Keratotic skin lesions and other risk factors are associated with skin cancer in organ-transplant recipients: a case-control study in The Netherlands, United Kingdom, Germany, France, and Italy. J Invest Dermatol; 2007 Jul;127(7):1647-56
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Keratotic skin lesions and other risk factors are associated with skin cancer in organ-transplant recipients: a case-control study in The Netherlands, United Kingdom, Germany, France, and Italy.
  • This study examines the association of keratotic skin lesions with the development of skin cancer in 915 solid organ-transplant recipients in five European countries.
  • In a hospital-based case-control study, cases with squamous- and basal-cell carcinoma were compared with controls without skin cancer.
  • Questionnaires, scrutiny of medical charts, and skin examination were delivered according to a standardized protocol.
  • Keratotic skin lesions and viral warts were counted on different body sites.
  • Keratotic skin lesions were strongly associated with an increased risk of squamous-cell carcinoma, with adjusted odds ratios of 4.1 (2.4;7.0) and 12.1 (6.1;24) for 1-49 and 50 and more keratotic skin lesions compared with no lesions, respectively.
  • Keratotic skin lesions were also associated with basal-cell carcinoma with adjusted odds ratios of 2.9 (1.7;4.9) and 4.0 (1.7;9.2) for 1-49 and 50 and more lesions, respectively.
  • Lighter skin types and painful sunburns were also significantly associated with an increased risk of squamous- and basal-cell carcinoma.
  • Keratotic skin lesions are strongly associated with skin cancer and are, thus, an important clinical criterion for identifying those organ-transplant recipients at an increased risk of skin cancers who should be offered more intensive skin surveillance.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Keratosis / epidemiology. Keratosis / pathology. Skin Neoplasms / etiology. Transplantation / adverse effects
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Europe / epidemiology. Female. Humans. Life Style. Male. Middle Aged. Papillomavirus Infections / epidemiology. Risk Factors. Sex Characteristics. Skin Pigmentation. Sunlight / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Rev Oncol Hematol. 2005 Oct;56(1):87-99 [15979889.001]
  • [Cites] J Am Acad Dermatol. 2000 Feb;42(2 Pt 1):307 [10642700.001]
  • [Cites] Transplantation. 2000 Jan 15;69(1):44-9 [10653378.001]
  • [Cites] J Clin Microbiol. 2000 Jun;38(6):2087-96 [10834958.001]
  • [Cites] J Med Virol. 2000 Jul;61(3):289-97 [10861635.001]
  • [Cites] Am J Kidney Dis. 2000 Jul;36(1):167-76 [10873887.001]
  • [Cites] Br J Dermatol. 2000 Sep;143(3):513-9 [10971322.001]
  • [Cites] Genes Dev. 2000 Dec 1;14(23):3065-73 [11114894.001]
  • [Cites] Transplantation. 2000 Nov 27;70(10):1479-84 [11118094.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):231-8 [11134217.001]
  • [Cites] J Photochem Photobiol B. 2001 Oct;63(1-3):8-18 [11684447.001]
  • [Cites] J Am Acad Dermatol. 2002 Jul;47(1):1-17; quiz 18-20 [12077575.001]
  • [Cites] EMBO J. 2002 Sep 2;21(17):4741-8 [12198176.001]
  • [Cites] Br J Dermatol. 2002 Nov;147(5):950-6 [12410706.001]
  • [Cites] N Engl J Med. 2003 Apr 24;348(17):1681-91 [12711744.001]
  • [Cites] Acta Otolaryngol. 2005 Sep;125(9):991-8 [16193590.001]
  • [Cites] Acta Derm Venereol. 2003;83(3):189-93 [12816154.001]
  • [Cites] Arch Dermatol. 2003 Jul;139(7):890-4 [12873884.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1221-7 [14520450.001]
  • [Cites] Arch Dermatol Res. 2003 Dec;295(7):273-9 [14618345.001]
  • [Cites] J Invest Dermatol. 2003 Dec;121(6):1531-5 [14675206.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1540-3 [14693751.001]
  • [Cites] N Engl J Med. 2004 Jun 24;350(26):2639-42 [15215478.001]
  • [Cites] Science. 2005 Sep 16;309(5742):1871-4 [16166520.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2695-700 [12750299.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 15;98(6):389-95 [16537831.001]
  • [Cites] Br J Dermatol. 2006 Mar;154(3):498-504 [16445782.001]
  • [Cites] Arch Dermatol. 2004 Sep;140(9):1079-85 [15381547.001]
  • [Cites] J Invest Dermatol. 2005 Jul;125(1):93-7 [15982308.001]
  • [Cites] J Clin Microbiol. 1999 Nov;37(11):3545-55 [10523550.001]
  • [Cites] Transplantation. 1996 Mar 15;61(5):715-21 [8607173.001]
  • [Cites] J Invest Dermatol. 1995 Sep;105(3):367-71 [7665914.001]
  • [Cites] Br J Dermatol. 1993 Sep;129(3):242-9 [8286220.001]
  • [Cites] N Engl J Med. 1991 Sep 19;325(12):843-8 [1875968.001]
  • [Cites] Acta Derm Venereol. 1990;70(6):491-4 [1981421.001]
  • [Cites] Transplantation. 1990 Mar;49(3):506-9 [2316011.001]
  • [Cites] Q J Med. 1987 Jul;64(243):609-16 [3313494.001]
  • [Cites] Lancet. 1984 Mar 31;1(8379):702-5 [6143041.001]
  • (PMID = 17380113.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / A6695
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2478722; NLM/ UKMS1916
  •  go-up   go-down


64. Krüger-Corcoran D, Stockfleth E, Jürgensen JS, Maltusch A, Nindl I, Sterry W, Lange-Asschenfeldt B, Ulrich C: [Human papillomavirus-associated warts in organ transplant recipients. Incidence, risk factors, management]. Hautarzt; 2010 Mar;61(3):220-9
MedlinePlus Health Information. consumer health - Warts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human papillomaviruses infect the squamous epithelia of the skin and cause warts, and are occasionally found in squamous cell carcinomas.
  • Since cell-mediated immunity plays a crucial role in the control of HPV-infections, organ transplant recipients, unable to mount an adequate T-helper 1 cell-mediated immune surveillance, frequently develop widespread and resistant induced warts.
  • Skin tumors, especially squamous cell carcinomas, are the most common post-transplantation neoplasm.
  • Warts, actinic keratoses and invasive squamous cell carcinomas are known to develop at the same time in the areas.
  • The role of HPV in the development of invasive squamous cell carcinoma under immunosuppression, remains to be elucidated in respect to common risk factors and increased numbers of warts potentially identifying patients at increased risk for carcinoma.
  • We prospectively studied 1690 organ transplant recipients in the dermatology clinic at the Charité University Hospital in Berlin, to evaluate risk factors being involved in the development of HPV-induced warts and to assess a potential association of with the development of non-melanoma skin cancers in this population.
  • The presence of more than 10 verrucae was associated with the development of actinic keratoses, invasive squamous cell carcinoma and basal cell carcinoma.
  • This study shows clear evidence that certain risk factors of skin carcinogenesis in organ transplant recipient such as increased age at transplantation, a high dose of immunosuppression related to a specific type of graft and use of azathioprine or cyclosporine are strongly associated with an increased incidence of warts.
  • Furthermore, HPV-induced verrucae vulgares could be used as a potential predictor for the development of coincidental non melanoma skin cancer in organ transplant recipients and therefore could serve as an early identification marker of skin cancer high-risk patients.
  • [MeSH-major] Carcinoma, Squamous Cell / epidemiology. Organ Transplantation / statistics & numerical data. Papillomaviridae. Postoperative Complications / epidemiology. Skin Neoplasms / epidemiology. Warts / epidemiology

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Liver Transpl. 2006 Dec;12(12):1883-7 [17133572.001]
  • [Cites] N Z Med J. 1995 Jun 28;108(1002):255-6 [7617333.001]
  • [Cites] Br J Dermatol. 1993 Mar;128(3):264-70 [8385983.001]
  • [Cites] Ann Dermatol Venereol. 2002 Mar;129(3):291-3 [11988683.001]
  • [Cites] Cancer Res. 1963 Sep;23:1226-43 [14070379.001]
  • [Cites] Recent Results Cancer Res. 2002;160:251-8 [12079221.001]
  • [Cites] Br J Dermatol. 2005 Jan;152(1):122-9 [15656812.001]
  • [Cites] J Invest Dermatol. 2007 Jul;127(7):1647-56 [17380113.001]
  • [Cites] Transpl Int. 2007 Mar;20(3):238-46 [17291217.001]
  • [Cites] Br J Dermatol. 2010 Jan;162(1):176-84 [19709100.001]
  • [Cites] Transplantation. 2000 Jan 15;69(1):44-9 [10653378.001]
  • [Cites] Acta Derm Venereol. 1991;71(1):63-6 [1711753.001]
  • [Cites] Am J Transplant. 2005 Feb;5(2):406-11 [15644002.001]
  • [Cites] Histopathology. 1989 Feb;14(2):129-39 [2540085.001]
  • [Cites] J R Soc Med. 1995 Feb;88(2):61-2 [7769594.001]
  • [Cites] Int Immunopharmacol. 2005 Jan;5(1):107-15 [15589468.001]
  • [Cites] Lancet. 1989 Jan 21;1(8630):124-9 [2563048.001]
  • [Cites] Clin Exp Dermatol. 2005 Nov;30(6):717-8 [16197401.001]
  • [Cites] Br J Dermatol. 2003 Nov;149 Suppl 66:20-4 [14616341.001]
  • [Cites] Arch Dermatol. 2004 Sep;140(9):1079-85 [15381547.001]
  • [Cites] Dermatol Ther. 2005 Jan-Feb;18(1):19-27 [15842609.001]
  • [Cites] J Am Acad Dermatol. 1997 Sep;37(3 Pt 1):445-9 [9308561.001]
  • [Cites] Dermatology. 2003;206(2):148-52 [12592083.001]
  • [Cites] Eur J Dermatol. 2007 Mar-Apr;17(2):140-5 [17337398.001]
  • [Cites] J Invest Dermatol. 2005 Jul;125(1):98-107 [15982309.001]
  • [Cites] Nephrol Dial Transplant. 1994;9(4):416-20 [8084456.001]
  • [Cites] Arch Dermatol. 2002 Jan;138(1):61-5 [11790168.001]
  • [Cites] Br J Dermatol. 2007 Apr;156(4):687-92 [17326748.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2695-700 [12750299.001]
  • [Cites] Ger Med Sci. 2004 Oct 29;2:Doc08 [19675691.001]
  • [Cites] Am J Kidney Dis. 2000 Jul;36(1):167-76 [10873887.001]
  • [Cites] Lasers Surg Med. 2002;30(2):135-40 [11870793.001]
  • [Cites] Laryngoscope. 2004 Jul;114(7):1151-6 [15235339.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 2):604-9 [15061843.001]
  • [Cites] Nature. 1957 Mar 30;179(4561):663-6 [13418758.001]
  • [Cites] Acta Derm Venereol. 2006;86(1):25-8 [16585985.001]
  • [Cites] Nephron. 1997;77(4):422-6 [9434064.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 2006 Oct;22(5):265-6 [16948830.001]
  • [Cites] Hautarzt. 2002 Aug;53(8):524-33 [12221466.001]
  • (PMID = 20165825.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


65. Wimmer E, Kraehn-Senftleben G, Issing WJ: HER3 expression in cutaneous tumors. Anticancer Res; 2008 Mar-Apr;28(2A):973-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In order to elucidate the role of the receptor tyrosine kinase HER3, the expression characteristics in different tissues of cutaneous malignancies and in normal skin were compared.
  • MATERIALS AND METHODS: In this study HER3 expression was evaluated by RT-PCR analysis and immunohistochemistry from different tissue specimens of cutaneous tumors like nevi, primary malignant melanomas, basal cell carcinoma, squamous cell carcinoma and malignant melanoma metastases and normal skin samples and graded into weak, moderate and strong expression.
  • Associations of tumor thickness in these specimens with HER3 expressions were also analyzed.
  • RESULTS: HER3 expression was found in 63% (10/16) of the basal cell carcinomas, in 4/5 of squamous cell carcinomas and in one Merkel cell carcinoma.
  • Within the group of different malignant melanomas, HER3 expression was detected in 35% of the nodular malignant melanomas (6/17) and in 9/19 of the superficial spreading melanomas, including 2 lentigo malignant melanomas.
  • The majority of melanomas with a higher tumor thickness expressed HER3, and 85% of melanoma metastasis were HER3-positive.
  • CONCLUSION: HER3 expression was associated with hyperproliferate tumor stages and suggested that HER3 expression could reflect an increased malignant potential in cutaneous lesions.
  • [MeSH-major] Skin Neoplasms / metabolism
  • [MeSH-minor] Carcinoma, Basal Cell / genetics. Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Humans. Immunohistochemistry. Melanoma / genetics. Melanoma / metabolism. Neoplasm Metastasis. Nevus. Receptor, ErbB-3 / genetics. Receptor, ErbB-3 / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Skin / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18507044.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-3
  •  go-up   go-down


71. Szeimies RM, Karrer S, Bäcker H: [Therapeutic options for epithelial skin tumors. Actinic keratoses, Bowen disease, squamous cell carcinoma, and basal cell carcinoma]. Hautarzt; 2005 May;56(5):430-40
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic options for epithelial skin tumors. Actinic keratoses, Bowen disease, squamous cell carcinoma, and basal cell carcinoma].
  • [Transliterated title] Therapieoptionen bei epithelialen Hauttumoren Aktinische Keratosen, Morbus Bowen, spinozelluläres Karzinom und Basalzellkarzinom.
  • There has been worldwide a significant rise in the incidence of epithelial skin tumors and their precursors in the past years with an increased number of younger patients affected.
  • In the following article different therapeutic approaches for actinic keratoses, Bowen's disease, basal cell carcinoma and squamous cell carcinoma are presented and analysed.
  • [MeSH-major] Risk Assessment / methods. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Bowen's Disease / diagnosis. Bowen's Disease / therapy. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Cryotherapy / methods. Curettage / methods. Humans. Keratosis / diagnosis. Keratosis / therapy. Practice Guidelines as Topic. Practice Patterns, Physicians'. Risk Factors

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Strahlenther Onkol. 2001 May;177(5):240-6 [11398609.001]
  • [Cites] Br J Dermatol. 2001 Mar;144(3):567-74 [11260016.001]
  • [Cites] Int J Dermatol. 2001 Nov;40(11):709-13 [11737438.001]
  • [Cites] J Am Acad Dermatol. 2001 Mar;44(3):462-70 [11209116.001]
  • [Cites] J Am Acad Dermatol. 1999 Sep;41(3 Pt 1):414-8 [10459115.001]
  • [Cites] Dermatologica. 1979;158(5):368-72 [437226.001]
  • [Cites] Int J Dermatol. 2004 Sep;43(9):687-92 [15357755.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):722-33 [15097956.001]
  • [Cites] Clin Exp Dermatol. 1999 Jul;24(4):338-9 [10457144.001]
  • [Cites] J Dermatol Surg Oncol. 1989 Apr;15(4):424-31 [2925988.001]
  • [Cites] J Am Acad Dermatol. 2002 Aug;47(2):258-62 [12140473.001]
  • [Cites] J Am Acad Dermatol. 1982 Nov;7(5):631-2 [7142470.001]
  • [Cites] J Drugs Dermatol. 2004 Jul-Aug;3(4):401-7 [15303784.001]
  • [Cites] Dermatol Surg. 2004 Sep;30(9):1214-8 [15355363.001]
  • [Cites] Br J Dermatol. 1999 Oct;141(4):633-41 [10583109.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2003 Mar;17(2):167-70 [12705745.001]
  • [Cites] Dermatol Surg. 2000 Aug;26(8):759-64 [10940063.001]
  • [Cites] Br J Dermatol. 2000 Apr;142(4):752-7 [10792227.001]
  • [Cites] Br J Dermatol. 2003 Nov;149 Suppl 66:43-9 [14616349.001]
  • [Cites] Br J Dermatol. 2004 Jul;151(1):148-56 [15270884.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):555-9 [10225444.001]
  • [Cites] Arch Dermatol. 2002 Nov;138(11):1498-502 [12437457.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 1):517-20 [15056141.001]
  • [Cites] Eur J Dermatol. 2002 Nov-Dec;12(6):558-61 [12459527.001]
  • [Cites] J Am Acad Dermatol. 1998 Mar;38(3):438-42 [9520026.001]
  • [Cites] Australas J Dermatol. 2000 Feb;41(1):19-30 [10715896.001]
  • [Cites] J Am Acad Dermatol. 2004 Oct;51(4):547-55 [15389189.001]
  • [Cites] Clin Dermatol. 2001 May-Jun;19(3):328-38 [11479045.001]
  • [Cites] Arch Dermatol. 2004 Oct;140(10 ):1284-5 [15492200.001]
  • [Cites] J Dermatolog Treat. 2003 Jun;14(2):99-106 [12775317.001]
  • [Cites] Br J Dermatol. 2004 Jul;151(1):141-7 [15270883.001]
  • [Cites] Br J Cancer. 1997;76(1):100-6 [9218740.001]
  • [Cites] Br J Dermatol. 2001 Apr;144(4):832-40 [11298545.001]
  • [Cites] Arch Dermatol. 2004 Oct;140(10 ):1286-7 [15492202.001]
  • [Cites] Br J Dermatol. 2003 Mar;148(3):539-43 [12653747.001]
  • [Cites] J Am Acad Dermatol. 1997 Jan;36(1):72-7 [8996264.001]
  • [Cites] Dermatol Surg. 2003 Nov;29(11):1150-3; discussion 1153 [14641346.001]
  • [Cites] Dermatol Surg. 2001 Feb;27(2):143-6 [11207687.001]
  • [Cites] J Am Acad Dermatol. 2003 Sep;49(3):483-6 [12963913.001]
  • [Cites] Lancet. 2004 Nov 13-19;364(9447):1766-72 [15541449.001]
  • [Cites] Br J Dermatol. 1996 Nov;135(5):766-71 [8977678.001]
  • [Cites] J Dermatol Surg Oncol. 1991 Sep;17(9):720-6 [1820764.001]
  • [Cites] Clin Radiol. 1986 Jan;37(1):33-4 [3514075.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):714-21 [15097955.001]
  • [Cites] Clin Ther. 2002 Jun;24(6):990-1000 [12117087.001]
  • [Cites] Lasers Surg Med. 2004;34(2):114-9 [15004822.001]
  • (PMID = 15815888.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 48
  •  go-up   go-down


72. Sharquie KE, Al-Meshhadani SA, Al-Nuaimy AA: Invasive squamous cell carcinoma of the eyes in patients with epidermodysplasia verruciformis. Saudi Med J; 2007 May;28(5):787-90
Genetic Alliance. consumer health - Epidermodysplasia Verruciformis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive squamous cell carcinoma of the eyes in patients with epidermodysplasia verruciformis.
  • They developed frequent multiple basal and squamous cell carcinoma, all of them had periorbital squamous cell carcinoma that invaded the orbit and ended with enucleation of their eyes.
  • [MeSH-major] Carcinoma, Squamous Cell / complications. Epidermodysplasia Verruciformis / complications. Orbital Neoplasms / complications
  • [MeSH-minor] Adult. Carcinoma, Basal Cell / complications. Eye Enucleation. Humans. Male

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17457453.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


73. McKnight CA, Wise AG, Maes RK, Howe C, Rector A, Van Ranst M, Kiupel M: Papillomavirus-associated basosquamous carcinoma in an Egyptian fruit bat (Rousettus aegyptiacus). J Zoo Wildl Med; 2006 Jun;37(2):193-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillomavirus-associated basosquamous carcinoma in an Egyptian fruit bat (Rousettus aegyptiacus).
  • Six additional variably sized, raised, smooth to cauliflower-like skin masses were observed randomly distributed throughout the left wing membranes.
  • Four masses were removed and diagnosed microscopically as basosquamous carcinomas and papillomas.
  • Additional masses, removed 6 mo and 1 yr later, showed bony invasion and squamous differentiation.
  • Polymerase chain reaction done on DNA extracts from formalin-fixed, paraffin-embedded tumor tissue amplified a 450 base-pair segment analogous to the L1 region of human papillomavirus types 96 and 5.
  • To our knowledge, this is the first report of papillomavirus-associated carcinoma in a chiropteran species.
  • [MeSH-major] Carcinoma, Squamous Cell / veterinary. Chiroptera / virology. Papillomaviridae / isolation & purification. Papillomavirus Infections / veterinary. Skin Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17312801.001).
  • [ISSN] 1042-7260
  • [Journal-full-title] Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians
  • [ISO-abbreviation] J. Zoo Wildl. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


74. Qureshi AA, Laden F, Colditz GA, Hunter DJ: Geographic variation and risk of skin cancer in US women. Differences between melanoma, squamous cell carcinoma, and basal cell carcinoma. Arch Intern Med; 2008 Mar 10;168(5):501-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Geographic variation and risk of skin cancer in US women. Differences between melanoma, squamous cell carcinoma, and basal cell carcinoma.
  • BACKGROUND: Occurrences of melanoma, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC) have been associated with varying geography.
  • Our goal was to evaluate differences in risk of these skin cancers according to residence at varying UV indices at 3 time points.
  • The outcome measure was diagnosis of melanoma, SCC, or BCC.
  • RESULTS: During the 18-year study, 420 cases of melanoma, 863 cases of SCC, and 8215 cases of BCC occurred.
  • Although elevated, the age-adjusted risk of BCC at 30 years of age associated with residence in these states was substantially less.
  • CONCLUSIONS: The risk of SCC is independently affected by residence in locations with medium and high UV indices; the gradient of risk is weaker for BCC; and the risk of melanoma does not change significantly across this gradient.


75. Downs N, Parisi A: Measurements of the anatomical distribution of erythemal ultraviolet: a study comparing exposure distribution to the site incidence of solar keratoses, basal cell carcinoma and squamous cell carcinoma. Photochem Photobiol Sci; 2009 Aug;8(8):1195-201
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Measurements of the anatomical distribution of erythemal ultraviolet: a study comparing exposure distribution to the site incidence of solar keratoses, basal cell carcinoma and squamous cell carcinoma.
  • The UV exposures were compared with existing data detailing the anatomical distribution of basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and solar keratoses (SK).
  • Surface UV exposures to unprotected skin surfaces have been presented for each of the face, neck, arm, hand and leg assessing a total of 1453 body sites (2491 measurements).
  • Further analysis with existing facial BCC and SK density data did not however show a direct relationship with the measured UV exposures highlighting the importance of other factors influencing the causation and localisation of facial NMSC.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Keratosis / epidemiology. Skin / pathology. Ultraviolet Rays

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19639123.001).
  • [ISSN] 1474-905X
  • [Journal-full-title] Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology
  • [ISO-abbreviation] Photochem. Photobiol. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


76. Skroza N, Panetta C, Schwartz RA, Balzani A, Rota C, Buccheri EM, Alfano C, Innocenzi D: Giant meta-typical carcinoma: an unusual tumor. Acta Dermatovenerol Croat; 2006;14(1):46-51
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant meta-typical carcinoma: an unusual tumor.
  • Meta-typical carcinoma (MTC) or basosquamous carcinoma is a remarkable malignancy with features of both basal and squamous cell carcinoma.
  • It is typically located on the back and face, often with clinical features of basal cell carcinoma but tending to be more aggressive with enhanced prospects of lymph node or distant metastases.
  • Our report describes a huge neglected MTC of the back of ten-year duration, a giant ulcero-vegetative tumor measuring 20 x 25 cm.
  • Histologic examination of specimens from the margins and periphery revealed aspects of both basal and squamous cell carcinoma, while the ulcerated center showed sclerotic tissue without tumor.
  • This may have been related to an intense inflammatory host response with elimination of neoplastic tissue and consequent local sclerosis evident in the central tumor-free portion.
  • This central tumor regression is to our knowledge a unique finding in MTC.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16603102.001).
  • [ISSN] 1330-027X
  • [Journal-full-title] Acta dermatovenerologica Croatica : ADC
  • [ISO-abbreviation] Acta Dermatovenerol Croat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


77. Weinstock MA: Controversies in the public health approach to keratinocyte carcinomas. Br J Dermatol; 2006 May;154 Suppl 1:3-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Controversies in the public health approach to keratinocyte carcinomas.
  • Keratinocyte carcinomas are very common cancers in fair-skinned populations throughout the world.
  • The term 'keratinocyte carcinoma' includes basal and squamous cell carcinoma of the skin, but not other cancers that may be included under the more ambiguous term 'nonmelanoma skin cancer'.
  • Mortality from keratinocyte carcinoma reveals distinct patterns suggestive of an important role of human papilloma virus infection.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16712708.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 1406-16-2 / Vitamin D
  • [Number-of-references] 12
  •  go-up   go-down


78. Mancuso M, Gallo D, Leonardi S, Pierdomenico M, Pasquali E, De Stefano I, Rebessi S, Tanori M, Scambia G, Di Majo V, Covelli V, Pazzaglia S, Saran A: Modulation of basal and squamous cell carcinoma by endogenous estrogen in mouse models of skin cancer. Carcinogenesis; 2009 Feb;30(2):340-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modulation of basal and squamous cell carcinoma by endogenous estrogen in mouse models of skin cancer.
  • Patched1 heterozygous mice (Ptch1(+/-)) are useful for basal cell carcinoma (BCC) studies, being remarkably susceptible to BCC induction by ultraviolet or ionizing radiation.
  • Analogously, skin carcinogenesis-susceptible (Car-S) mice are elective for studies of papilloma and squamous cell carcinoma (SCC) induction.
  • We previously reported a striking effect of gender on BCC induction in Ptch1(+/-) mice, with total resistance of females; likewise, Car-S females show increased skin tumor resistance relative to males.
  • Here, we investigated the protective role of endogenous estrogen in skin keratinocyte tumorigenesis.
  • Control (CN) and ovariectomized Ptch1(+/-) or Car-S females were irradiated for BCC induction or topically treated with chemical carcinogens for SCC induction.
  • Susceptibility to BCC or SCC was dramatically increased in ovariectomized Ptch1(+/-) and Car-S females and restored to levels observed in males.
  • Remarkably, progression of initially benign papillomas to malignant SCC occurred only in ovariectomized Car-S females.
  • We explored the mechanisms underlying tumor progression and report overexpression of estrogen receptor (ER)-alpha, downregulation of ERbeta and upregulation of cyclin D1 in papillomas from ovariectomized Car-S relative to papillomas from CN females.
  • Thus, an imbalanced ERalpha/ERbeta expression may be associated with estrogen-mediated modulation of non-melanoma skin carcinogenesis, with a key role played by cyclin D1.
  • Our findings underscore a highly protective role of endogenous estrogen against skin tumorigenesis by diverse agents in two independent mouse models of skin cancer.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Estrogens / physiology. Skin Neoplasms / metabolism
  • [MeSH-minor] Animals. Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. Cyclin D1 / metabolism. Disease Models, Animal. Estrogen Receptor alpha / metabolism. Estrogen Receptor beta / metabolism. Female. Male. Mice. Neoplasms, Radiation-Induced / metabolism. Neoplasms, Radiation-Induced / pathology. Ovariectomy. Papilloma / metabolism. Papilloma / pathology. Receptors, Cell Surface / genetics. Receptors, Cell Surface / metabolism. Ultraviolet Rays


79. Ball EA, Hussain M, Moss AL: Squamous cell carcinoma and basal cell carcinoma arising in a naevus sebaceous of Jadassohn: case report and literature review. Clin Exp Dermatol; 2005 May;30(3):259-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma and basal cell carcinoma arising in a naevus sebaceous of Jadassohn: case report and literature review.
  • The development of a basal cell carcinoma within a naevus sebaceous of Jadassohn (NSJ) has commonly been reported.
  • However, the development of a squamous cell carcinoma (SCC) is rare.
  • Of these only one was a case of simultaneous occurrence of squamous and basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Carcinoma, Squamous Cell / etiology. Neoplasms, Multiple Primary / etiology. Nevus / complications. Sebaceous Gland Neoplasms / complications
  • [MeSH-minor] Adult. Humans. Male. Skin Neoplasms / etiology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Moles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15807685.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 10
  •  go-up   go-down


80. Gremmel T, Wild S, Schuller W, Kürten V, Dietz K, Krutmann J, Berneburg M: Six genes associated with the clinical phenotypes of individuals with deficient and proficient DNA repair. Transl Oncogenomics; 2008 Feb 10;3:1-13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Xeroderma pigmentosum (XP) is a genetic disorder characterised by hypo-/hyperpigmentation, increased sensitivity to ultraviolet (UV)-radiation and an up to 2000-fold increased skin cancer risk.
  • This defect accounts for their mutator phenotype but does not predict their increased skin cancer risk.
  • Therefore, we carried out array analysis to measure the expression of more than 1000 genes after UVB-irradiation in XP cells from three complementation groups with different clinical severity (XP-A, XP-D, XP-F) as well as from patients with normal DNA repair but increased skin cancer risk (≥2 basal or squamous cell carcinoma at age <40yrs).
  • Genes identified in XP cells could be confirmed in cells from patients with no known DNA repair defects but increased skin cancer risk.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mutat Res. 1980 Jan;69(1):177-90 [6987495.001]
  • [Cites] Cancer Res. 1989 Nov 1;49(21):6162-3 [2676158.001]
  • [Cites] Arch Dermatol. 1987 Feb;123(2):241-50 [3545087.001]
  • [Cites] Science. 2000 Sep 8;289(5485):1670-2 [11001727.001]
  • [Cites] Adv Genet. 2001;43:71-102 [11037299.001]
  • [Cites] Genes Dev. 1999 Apr 1;13(7):768-85 [10197977.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):431-8 [10667598.001]
  • [Cites] EMBO J. 2000 Mar 1;19(5):1157-66 [10698956.001]
  • [Cites] J Photochem Photobiol B. 2000 Feb;54(2-3):87-93 [10836536.001]
  • [Cites] Nature. 2000 Aug 3;406(6795):532-5 [10952316.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4797-808 [11406555.001]
  • [Cites] Mol Cell. 2001 Jul;8(1):213-24 [11511374.001]
  • [Cites] Nat Cell Biol. 2002 Jan;4(1):26-31 [11780128.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2923-8 [12019173.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3759-65 [12097286.001]
  • [Cites] Mol Cell. 2003 Jun;11(6):1635-46 [12820975.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5 [12883005.001]
  • [Cites] Mutat Res. 2003 Nov;544(2-3):107-14 [14644313.001]
  • [Cites] J Dermatol Sci. 2004 May;34(3):185-94 [15113588.001]
  • [Cites] FASEB J. 2004 Oct;18(13):1559-61 [15289447.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6511-23 [15374962.001]
  • [Cites] Oncogene. 2005 Feb 17;24(8):1359-74 [15608684.001]
  • [Cites] J Exp Med. 2005 Jan 17;201(2):173-9 [15657287.001]
  • [Cites] Mutat Res. 2005 Apr 1;571(1-2):43-56 [15748637.001]
  • [Cites] Photochem Photobiol Sci. 2002 Sep;1(9):656-64 [12665302.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jul 11;306(4):1026-36 [12821146.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6837-41 [9192652.001]
  • (PMID = 21566739.001).
  • [Journal-full-title] Translational oncogenomics
  • [ISO-abbreviation] Transl Oncogenomics
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3022359
  • [Keywords] NOTNLM ; DNA repair / array analysis / basal cell carcinoma / skin cancer risk / squamous cell carcinoma / xeroderma pigmentosum
  •  go-up   go-down


81. Testori A, Tosti G, Martinoli C, Spadola G, Cataldo F, Verrecchia F, Baldini F, Mosconi M, Soteldo J, Tedeschi I, Passoni C, Pari C, Di Pietro A, Ferrucci PF: Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach. Dermatol Ther; 2010 Nov-Dec;23(6):651-61
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach.
  • Electroporation uses pulsed, high-intensity electric fields to temporarily increase cell membrane permeability by creation of pores, through which small molecules, such as chemotherapeutic agents, can diffuse inside cells before they reseal.
  • ECT has already been proven to be effective in diverse tumor histotypes, including melanoma and basal and squamous cell carcinoma, Kaposi sarcoma, and breast cancer, also in those cases nonresponding to classical chemotherapies or other loco-regional treatment modalities, with a good safety profile.
  • ECT can be proposed as loco-regional therapy for disseminated cutaneous and subcutaneous tumor lesions as alternative treatment modality to conventional therapies or as palliative care, in order to improve patients' quality of life.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Electrochemotherapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Animals. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Humans. Skin / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Wiley Periodicals, Inc.
  • (PMID = 21054709.001).
  • [ISSN] 1529-8019
  • [Journal-full-title] Dermatologic therapy
  • [ISO-abbreviation] Dermatol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 11056-06-7 / Bleomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


82. Wells MJ, Taylor RS: Mohs micrographic surgery for penoscrotal malignancy. Urol Clin North Am; 2010 Aug;37(3):403-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Specific penoscrotal neoplasias discussed in this article include invasive and in situ squamous cell carcinoma, basal cell carcinoma, extramammary Paget disease, and granular cell tumor.
  • [MeSH-minor] Carcinoma, Squamous Cell / surgery. Humans. Male. Paget Disease, Extramammary / surgery. Penile Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20674695.001).
  • [ISSN] 1558-318X
  • [Journal-full-title] The Urologic clinics of North America
  • [ISO-abbreviation] Urol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Applebaum KM, Karagas MR, Hunter DJ, Catalano PJ, Byler SH, Morris S, Nelson HH: Polymorphisms in nucleotide excision repair genes, arsenic exposure, and non-melanoma skin cancer in New Hampshire. Environ Health Perspect; 2007 Aug;115(8):1231-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in nucleotide excision repair genes, arsenic exposure, and non-melanoma skin cancer in New Hampshire.
  • UV damage is specifically repaired by nucleotide excision repair (NER), and common genetic variants in NER may increase risk for non-melanoma skin cancer (NMSC).
  • METHODS: Incident cases of basal and squamous cell carcinoma (BCC and SCC, respectively) were identified through a network of dermatologists and pathology laboratories across New Hampshire.
  • The analysis included 880 cases of BCC, 666 cases of SCC, and 780 controls.
  • RESULTS: There was an increased BCC risk associated with high arsenic exposure among those homozygous variant for XPA [odds ratio (OR) = 1.8; 95% confidence interval (CI), 0.9-3.7].
  • For XPD, having variation at both loci (312Asn and 751Gln) occurred less frequently among BCC and SCC cases compared with controls (OR = 0.8; 95% CI, 0.6-1.0) for both case groups.

  • MedlinePlus Health Information. consumer health - Arsenic.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Environ Health Perspect. 1998 Aug;106 Suppl 4:1047-50 [9703491.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Jan;8(1):77-81 [9950243.001]
  • [Cites] Toxicol Lett. 1998 Dec 28;102-103:235-9 [10022259.001]
  • [Cites] Oncol Res. 1998;10(9):475-82 [10223623.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):555-9 [10225444.001]
  • [Cites] Toxicol Appl Pharmacol. 1999 Aug 15;159(1):65-75 [10448126.001]
  • [Cites] Carcinogenesis. 2002 Feb;23(2):295-9 [11872635.001]
  • [Cites] Environ Health Perspect. 1999 Sep;107(9):727-9 [10464073.001]
  • [Cites] Prensa Med Argent. 1964 Oct 23;51:994-8 [14231402.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Nov;13(11 Pt 1):1788-93 [15533908.001]
  • [Cites] Carcinogenesis. 2004 Dec;25(12):2433-41 [15333465.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2242-6 [15598786.001]
  • [Cites] Hum Mutat. 2005 Apr;25(4):353-9 [15776433.001]
  • [Cites] Cancer Lett. 2005 May 26;222(2):205-9 [15863269.001]
  • [Cites] Carcinogenesis. 2000 Apr;21(4):551-5 [10753184.001]
  • [Cites] Carcinogenesis. 2000 May;21(5):965-71 [10783319.001]
  • [Cites] J Natl Cancer Inst. 2000 Jun 7;92(11):874-97 [10841823.001]
  • [Cites] Pharmacology. 2000 Sep;61(3):212-27 [10971208.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1354-7 [11245433.001]
  • [Cites] Am J Epidemiol. 2001 Mar 15;153(6):559-65 [11257063.001]
  • [Cites] Carcinogenesis. 2001 Apr;22(4):593-7 [11285194.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3321-5 [11309287.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Apr;10(4):355-60 [11319176.001]
  • [Cites] Carcinogenesis. 2001 Jun;22(6):899-904 [11375896.001]
  • [Cites] Mutat Res. 2001 Jul 1;478(1-2):159-68 [11406180.001]
  • [Cites] Carcinogenesis. 2001 Aug;22(8):1185-8 [11470747.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 Dec 1;177(2):132-48 [11740912.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):152-5 [11782372.001]
  • [Cites] Carcinogenesis. 2002 Apr;23(4):599-603 [11960912.001]
  • [Cites] Int J Hyg Environ Health. 2002 Mar;205(1-2):85-94 [12018020.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):993-7 [12376498.001]
  • [Cites] Mutat Res. 2002 Nov 30;509(1-2):165-74 [12427537.001]
  • [Cites] J Invest Dermatol. 2003 Jan;120(1):48-55 [12535197.001]
  • [Cites] Int J Cancer. 2003 Apr 10;104(3):263-8 [12569548.001]
  • [Cites] Carcinogenesis. 2003 Mar;24(3):505-9 [12663511.001]
  • [Cites] Toxicol Lett. 2003 Jul 20;143(2):123-31 [12749816.001]
  • [Cites] Mutat Res. 2003 Dec 10;533(1-2):37-65 [14643412.001]
  • [Cites] Mutagenesis. 2004 Mar;19(2):143-8 [14981161.001]
  • [Cites] Carcinogenesis. 2004 May;25(5):729-34 [14688016.001]
  • [Cites] Br J Cancer. 2004 Oct 18;91(8):1604-9 [15381933.001]
  • [Cites] J Natl Cancer Inst. 1968 Mar;40(3):453-63 [5644201.001]
  • [Cites] Beitr Pathol. 1974 Apr;151(4):384-400 [4838015.001]
  • [Cites] Can Med Assoc J. 1975 Sep 6;113(5):396-401 [125622.001]
  • [Cites] Am J Epidemiol. 1976 Dec;104(6):609-20 [998608.001]
  • [Cites] Hum Toxicol. 1983 Jan;2(1):121-33 [6840787.001]
  • [Cites] Cancer Res. 1985 Nov;45(11 Pt 2):5895-9 [4053060.001]
  • [Cites] J Mol Biol. 1987 Aug 20;196(4):947-50 [3681984.001]
  • [Cites] J Clin Epidemiol. 1989;42(4):317-24 [2723692.001]
  • [Cites] Mol Toxicol. 1989 Winter;2(1):1-9 [2615768.001]
  • [Cites] Biol Trace Elem Res. 1989 Jul-Sep;21:373-81 [2484616.001]
  • [Cites] Biol Met. 1991;4(4):197-200 [1777354.001]
  • [Cites] Mutagenesis. 1992 Jan;7(1):51-5 [1635456.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1993 Sep-Oct;2(5):493-7 [8220096.001]
  • [Cites] Mutat Res. 2005 Jul 1;574(1-2):105-11 [15914210.001]
  • [Cites] Cancer Detect Prev. 2005;29(3):209-14 [15936590.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1539-44 [15941969.001]
  • [Cites] Mutat Res. 2006 Jun;612(3):215-46 [16574468.001]
  • [Cites] Environ Health Perspect. 2006 Aug;114(8):1193-8 [16882524.001]
  • [Cites] Carcinogenesis. 2006 Aug;27(8):1670-5 [16513681.001]
  • [Cites] Carcinogenesis. 2007 Mar;28(3):672-6 [17050553.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 2004;84:1-477 [15645577.001]
  • [Cites] Am J Epidemiol. 1994 Oct 1;140(7):598-607 [7942760.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):109-14 [7819025.001]
  • [Cites] Mamm Genome. 1996 Aug;7(8):563-74 [8679005.001]
  • [Cites] Carcinogenesis. 1997 Feb;18(2):399-405 [9054635.001]
  • [Cites] Mutat Res. 1997 Jun;386(3):345-51 [9219571.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Aug;6(8):589-96 [9264271.001]
  • [Cites] Epidemiology. 1997 Sep;8(5):545-50 [9270957.001]
  • [Cites] Trends Biochem Sci. 1998 Jan;23(1):1-4 [9478126.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):604-8 [9485007.001]
  • [Cites] Mutat Res. 1998 Feb;407(1):25-34 [9539978.001]
  • (PMID = 17687452.001).
  • [ISSN] 0091-6765
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA057494; United States / NCI NIH HHS / CA / R01CA082354; United States / NIEHS NIH HHS / ES / P42 ES007373; United States / NIEHS NIH HHS / ES / T32 ES07155; United States / NIEHS NIH HHS / ES / P42 ES07373; United States / NCI NIH HHS / CA / R01CA57494; United States / NIEHS NIH HHS / ES / T32 ES007155; United States / NCI NIH HHS / CA / R01 CA082354
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Environmental Pollutants; 0 / XPA protein, human; 0 / Xeroderma Pigmentosum Group A Protein; EC 3.6.4.12 / Xeroderma Pigmentosum Group D Protein; EC 5.99.- / ERCC2 protein, human; N712M78A8G / Arsenic
  • [Other-IDs] NLM/ PMC1940098
  •  go-up   go-down


84. Harrison SC, Bergfeld WF: Ultraviolet light and skin cancer in athletes. Sports Health; 2009 Jul;1(4):335-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultraviolet light and skin cancer in athletes.
  • The incidence of melanoma and nonmelanoma skin cancers is increasing worldwide.
  • Ultraviolet light exposure is the most important risk factor for cutaneous melanoma and nonmelanoma skin cancers.
  • Nonmelanoma skin cancer includes basal cell carcinoma and squamous cell carcinoma.
  • Constitutive skin color and genetic factors, as well as immunological factors, play a role in the development of skin cancer.
  • Ultraviolet light also causes sunburn and photoaging damage to the skin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 1996 Dec;35(6):1012-3 [8959974.001]
  • [Cites] J Am Acad Dermatol. 2008 Aug;59(2):316-23 [18485529.001]
  • [Cites] J Am Acad Dermatol. 1999 Jan;40(1):114-6 [9922027.001]
  • [Cites] J Cosmet Dermatol. 2006 Mar;5(1):39-47 [17173570.001]
  • [Cites] JAMA. 2006 Dec 20;296(23):2832-8 [17179460.001]
  • [Cites] J Am Acad Dermatol. 2008 May;58(5 Suppl 2):S129-32 [18410798.001]
  • [Cites] Acta Clin Croat. 2008 Mar;47(1):25-30 [18714644.001]
  • [Cites] Dermatology. 2000;201(1):44-5 [10971059.001]
  • [Cites] Br J Dermatol. 2001 Mar;144(3):471-5 [11260001.001]
  • [Cites] Med Sci Sports Exerc. 2001 Aug;33(8):1385-6 [11474342.001]
  • [Cites] Sports Med. 2002;32(5):309-21 [11929358.001]
  • [Cites] J Am Acad Dermatol. 2003 Mar;48(3):367-75 [12637916.001]
  • [Cites] J Am Acad Dermatol. 2005 Aug;53(2):237-41 [16021116.001]
  • [Cites] Arch Dermatol. 2005 Aug;141(8):1032-4 [16103334.001]
  • [Cites] J Cutan Pathol. 2006 Mar;33(3):191-206 [16466506.001]
  • [Cites] J Cutan Pathol. 2006 Apr;33(4):261-79 [16630176.001]
  • [Cites] J Am Acad Dermatol. 2006 Jul;55(1):1-19 [16781287.001]
  • [Cites] Arch Dermatol. 2006 Nov;142(11):1471-4 [17116838.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1116-22 [17131335.001]
  • [Cites] Am J Prev Med. 2007 Mar;32(3):210-6 [17296473.001]
  • [Cites] FDA Consum. 2006 Sep-Oct;40(5):4 [17326301.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Aug;4(8):462-9 [17657251.001]
  • [Cites] Br J Dermatol. 2007 Dec;157 Suppl 2:47-51 [18067632.001]
  • [Cites] Clin Dermatol. 2008 Jan-Feb;26(1):12-5 [18280899.001]
  • [Cites] Adv Exp Med Biol. 2008;624:89-103 [18348450.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2008 May;22(5):606-15 [18410618.001]
  • [Cites] Int J Sport Nutr Exerc Metab. 2008 Apr;18(2):204-24 [18458363.001]
  • [Cites] South Med J. 1997 Jan;90(1):55-8 [9003825.001]
  • (PMID = 23015891.001).
  • [ISSN] 1941-7381
  • [Journal-full-title] Sports health
  • [ISO-abbreviation] Sports Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3445124
  • [Keywords] NOTNLM ; athletes / melanoma / skin cancer / ultraviolet light
  •  go-up   go-down


85. Lim P, Paver R, Peñas PF: Mohs micrographic surgery at the Skin and Cancer Foundation Australia, 10 years later (1997 vs 2007). J Am Acad Dermatol; 2010 Nov;63(5):832-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mohs micrographic surgery at the Skin and Cancer Foundation Australia, 10 years later (1997 vs 2007).
  • OBJECTIVE: We sought to evaluate changes over time in the type of patients and skin cancers that are treated using MMS, and the repairs used to close the defects.
  • METHODS: We conducted a retrospective study on patients treated with MMS at the Skin and Cancer Foundation Australia, Westmead, in 1997 against those treated in 2007.
  • Patient demographics (age, sex), pathology of tumor, anatomic site of the tumor, preoperative tumor size, postoperative defect size, and repair method were analyzed.
  • The 2007 cohort was a little older (62 vs 64 years), but there were no differences in sex, anatomic site, rate of basal/squamous cell carcinoma, squamous cell carcinoma histologic subtypes, or preoperative tumor size.
  • However, there were fewer superficial basal cell carcinomas, and the postoperative defect size was smaller in 2007 (P < .0001).
  • CONCLUSION: Although tumor size and the percentage of tumors in each anatomic site did not change over 10 years, the size of the defect created after MMS has become smaller.
  • This reduction in defect size may explain why more defects are now repaired by side-to-side closure and flap repairs whereas fewer defects are repaired by skin grafting.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Mohs Surgery / statistics & numerical data. Mohs Surgery / utilization. Skin Neoplasms / surgery
  • [MeSH-minor] Aged. Australia / epidemiology. Cohort Studies. Female. Humans. Male. Middle Aged. Retrospective Studies. Skin Transplantation / statistics & numerical data. Skin Transplantation / utilization. Surgical Flaps / statistics & numerical data. Surgical Flaps / utilization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20950738.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Chew YK, Noorizan Y, Khir A, Brito-Mutunayagam S, Prepagaran N: The use of paramedian forehead flap reconstruction after wide excision of basal cell carcinoma of the nose. Med J Malaysia; 2008 Oct;63(4):339-40
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of paramedian forehead flap reconstruction after wide excision of basal cell carcinoma of the nose.
  • Basal cell carcinoma (BCC) is an indolent, slow-growing malignant skin tumour.
  • The nose is a common site for malignant skin tumours, such as basal cell carcinoma and squamous cell carcinoma because it is exposed to the sun.
  • Excision of the BCC will leave the nose with a soft tissue defect which requires reconstruction.
  • This report illustrates a case of BCC of nose whereby a wide excision and reconstruction was performed with a paramedian forehead flap.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Nose Neoplasms / surgery. Rhinoplasty / methods. Surgical Flaps

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19385500.001).
  • [ISSN] 0300-5283
  • [Journal-full-title] The Medical journal of Malaysia
  • [ISO-abbreviation] Med. J. Malaysia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Malaysia
  •  go-up   go-down


87. Steele CL, Shea CR, Petronic-Rosic V: Epidermolytic hyperkeratosis within infundibular cysts. J Cutan Pathol; 2007 Apr;34(4):360-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EH has been observed as an incidental finding in tissue adjacent to and within lesions such as nevi, scars, malignant melanoma, squamous cell carcinoma, basal cell carcinoma, and seborrheic keratoses.
  • We present two cases of EH within infundibular type follicular cysts, a rare finding only once otherwise reported in 1978.
  • [MeSH-minor] Aged. Carcinoma, Basal Cell / complications. Carcinoma, Squamous Cell / complications. Female. Humans. Incidental Findings. Male. Skin Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17381810.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


88. Pons M, Quintanilla M: Molecular biology of malignant melanoma and other cutaneous tumors. Clin Transl Oncol; 2006 Jul;8(7):466-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular biology of malignant melanoma and other cutaneous tumors.
  • Skin cancer is the most common cancer worldwide.
  • In this review, we summarize the most important genetic changes contributing to the development of malignant melanoma, basal cell carcinoma and squamous cell carcinoma, the main tumor entities arising in the skin.
  • While our understanding of the oncogenes and tumor suppressor genes involved in the development and progression of skin tumors is still fragmentary, recent advances have shown alterations affecting conserved signalling pathways that control cellular proliferation and viability.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Cell Transformation, Neoplastic. Genes, Tumor Suppressor. Melanoma / pathology. Oncogenes. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2002 May;2(5):361-72 [12044012.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13312-7 [11606789.001]
  • [Cites] J Natl Cancer Inst. 2000 Jun 21;92(12):1006-10 [10861313.001]
  • [Cites] N Engl J Med. 2005 Nov 24;353(21):2262-9 [16306523.001]
  • [Cites] Mutat Res. 2005 Apr 1;571(1-2):65-79 [15748639.001]
  • [Cites] Am J Med Genet C Semin Med Genet. 2004 Nov 15;131C(1):82-92 [15468170.001]
  • [Cites] J Cutan Pathol. 2005 Mar;32(3):191-205 [15701081.001]
  • [Cites] Nat Med. 1999 Nov;5(11):1285-91 [10545995.001]
  • [Cites] Nat Genet. 1996 Sep;14 (1):78-81 [8782823.001]
  • [Cites] Lancet. 2002 Jan 5;359(9300):7-8 [11809177.001]
  • [Cites] Int J Dermatol. 2003 Sep;42(9):669-76 [12956675.001]
  • [Cites] Pediatrics. 2004 Apr;113(4 Suppl):1114-9 [15060207.001]
  • [Cites] Nat Rev Cancer. 2003 Aug;3(8):559-70 [12894244.001]
  • [Cites] Cancer Metastasis Rev. 1999;18(2):261-84 [10728988.001]
  • [Cites] Cancer Lett. 2005 Jul 28;225(2):181-92 [15978322.001]
  • [Cites] Semin Cancer Biol. 2004 Feb;14(1):63-9 [14757536.001]
  • [Cites] Cancer Cell. 2005 Dec;8(6):439-41 [16338657.001]
  • [Cites] Carcinogenesis. 2005 Oct;26(10):1657-67 [15905207.001]
  • [Cites] Cancer Lett. 2005 Dec 18;230(2):153-86 [16297704.001]
  • [Cites] J Invest Dermatol. 2004 May;122(5):1284-92 [15140233.001]
  • [Cites] Br J Dermatol. 2005 Jun;152(6):1108-24 [15948971.001]
  • [Cites] Mutat Res. 2005 Apr 1;571(1-2):43-56 [15748637.001]
  • [Cites] Nature. 1994 Dec 22-29;372(6508):773-6 [7997263.001]
  • (PMID = 16870533.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Italy
  • [Number-of-references] 23
  •  go-up   go-down


89. Perkins W: Who should have Mohs micrographic surgery? Curr Opin Otolaryngol Head Neck Surg; 2010 Aug;18(4):283-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: To review the indications for Mohs micrographic surgery in skin cancer particularly with relationship to tumours of the head and neck and any recent developments which may influence those indications in the near future.
  • RECENT FINDINGS: There is increasing evidence to support the use of Mohs micrographic surgery in the treatment of recurrent and primary basal cell carcinoma and in squamous cell carcinoma, particularly when there is evidence of perineural invasion.
  • [MeSH-major] Mohs Surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Decision Making. Dermatofibrosarcoma / surgery. Histiocytoma, Benign Fibrous / surgery. Humans. Melanoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20613530.001).
  • [ISSN] 1531-6998
  • [Journal-full-title] Current opinion in otolaryngology & head and neck surgery
  • [ISO-abbreviation] Curr Opin Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


90. Vaid M, Katiyar SK: Molecular mechanisms of inhibition of photocarcinogenesis by silymarin, a phytochemical from milk thistle (Silybum marianum L. Gaertn.) (Review). Int J Oncol; 2010 May;36(5):1053-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Changes in life style over the past several decades including much of the time spent outdoors and the use of tanning devices for cosmetic purposes by individuals have led to an increase in the incidence of solar ultraviolet (UV) radiation-induced skin diseases including the risk of skin cancers.
  • Solar UV radiations are considered as the most prevalent environmental carcinogens, and chronic exposure of the skin to UV leads to squamous and basal cell carcinoma and melanoma in human population.
  • Silymarin is one of them and extensively studied for its skin photoprotective capabilities.
  • ), and has been shown to have chemopreventive effects against photocarcinogenesis in mouse tumor models.
  • Topical treatment of silymarin inhibited photocarcinogenesis in mice in terms of tumor incidence, tumor multiplicity and growth of the tumors.
  • It is suggested that silymarin may favorably supplement sunscreen protection, and may be useful for skin diseases associated with solar UV radiation-induced inflammation, oxidative stress and immunomodulatory effects.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1993 Apr 23;260(5107):496-7 [8097337.001]
  • [Cites] Science. 1993 Apr 23;260(5107):547-9 [8097338.001]
  • [Cites] J Natl Cancer Inst. 1993 Jun 2;85(11):846-8 [8388060.001]
  • [Cites] Immunol Today. 1993 Jul;14(7):335-8 [8103338.001]
  • [Cites] N Engl J Med. 1993 Oct 14;329(16):1147-51 [8377777.001]
  • [Cites] Photochem Photobiol. 1993 Dec;58(6):813-7 [8310001.001]
  • [Cites] J Am Acad Dermatol. 1994 May;30(5 Pt 1):774-8 [8176018.001]
  • [Cites] Carcinogenesis. 1994 Jun;15(6):1099-103 [8020140.001]
  • [Cites] J Invest Dermatol. 1994 Aug;103(2):211-6 [8040612.001]
  • [Cites] J Leukoc Biol. 1994 Dec;56(6):769-75 [7996051.001]
  • [Cites] Arch Dermatol. 1995 Feb;131(2):170-5 [7857113.001]
  • [Cites] J Immunol. 1995 May 15;154(10):5114-20 [7730617.001]
  • [Cites] J Immunol. 1995 Nov 15;155(10):4661-8 [7594465.001]
  • [Cites] Photochem Photobiol. 1995 Nov;62(5):855-61 [8570723.001]
  • [Cites] J Cell Biol. 1996 Apr;133(1):211-20 [8601609.001]
  • [Cites] J Biol Chem. 1996 Apr 5;271(14):8285-94 [8626523.001]
  • [Cites] Cancer Res. 1996 Mar 1;56(5):1023-30 [8640756.001]
  • [Cites] J Invest Dermatol. 1996 Jun;106(6):1187-91 [8752655.001]
  • [Cites] Photochem Photobiol. 1996 Apr;63(4):356-7 [8934734.001]
  • [Cites] Photochem Photobiol. 1996 Apr;63(4):380-3 [8934743.001]
  • [Cites] J Immunol. 1996 Dec 15;157(12):5254-61 [8955170.001]
  • [Cites] J Natl Cancer Inst. 1997 Apr 16;89(8):556-66 [9106644.001]
  • [Cites] Int J Oncol. 2002 Dec;21(6):1213-22 [12429970.001]
  • [Cites] Carcinogenesis. 2003 May;24(5):927-36 [12771038.001]
  • [Cites] Carcinogenesis. 2003 Aug;24(8):1379-88 [12807737.001]
  • [Cites] J Invest Dermatol. 2003 Oct;121(4):862-8 [14632206.001]
  • [Cites] J Invest Dermatol. 2004 Feb;122(2):510-7 [15009738.001]
  • [Cites] J Am Acad Dermatol. 1998 May;38(5 Pt 1):681-6 [9591810.001]
  • [Cites] J Cell Biochem Suppl. 1997;27:59-67 [9591194.001]
  • [Cites] J Invest Dermatol. 1998 Jun;110(6):966-71 [9620307.001]
  • [Cites] Br J Dermatol. 1998 Jul;139(1):3-10 [9764141.001]
  • [Cites] J Am Acad Dermatol. 1998 Oct;39(4 Pt 1):611-25 [9777769.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):622-32 [9973210.001]
  • [Cites] Nat Med. 1999 Apr;5(4):418-22 [10202931.001]
  • [Cites] Br J Dermatol. 1999 Feb;140(2):255-8 [10233218.001]
  • [Cites] J Invest Dermatol. 1999 May;112(5):751-6 [10233767.001]
  • [Cites] J Am Acad Dermatol. 1999 May;40(5 Pt 1):697-701 [10321596.001]
  • [Cites] Am J Health Syst Pharm. 1999 Jun 15;56(12):1195-7 [10484652.001]
  • [Cites] Lancet. 1999 Aug 28;354(9180):723-9 [10475183.001]
  • [Cites] Carcinogenesis. 2005 Aug;26(8):1404-13 [15831527.001]
  • [Cites] Mol Cancer Ther. 2006 Jul;5(7):1660-8 [16891451.001]
  • [Cites] J Dermatol Sci. 2007 Apr;46(1):21-30 [17289350.001]
  • [Cites] J Dermatol Sci. 2007 Dec;48(3):213-24 [17689055.001]
  • [Cites] Photochem Photobiol. 2008 Mar-Apr;84(2):266-71 [18221354.001]
  • [Cites] J Invest Dermatol. 2009 May;129(5):1258-70 [19020550.001]
  • [Cites] Cancer Prev Res (Phila). 2010 Feb;3(2):179-89 [20103727.001]
  • [Cites] J Exp Med. 1998 Apr 6;187(7):1133-8 [9529329.001]
  • [Cites] J Investig Dermatol Symp Proc. 1999 Sep;4(1):97-100 [10537017.001]
  • [Cites] Carcinogenesis. 1999 Nov;20(11):2117-24 [10545414.001]
  • [Cites] Cancer Lett. 1999 Dec 1;147(1-2):77-84 [10660092.001]
  • [Cites] Int Urol Nephrol. 1999;31(4):417-22 [10668934.001]
  • [Cites] J Heart Lung Transplant. 2000 Mar;19(3):249-55 [10713249.001]
  • [Cites] Liver Transpl. 2000 May;6(3):253-62 [10827224.001]
  • [Cites] Carcinogenesis. 2001 Feb;22(2):287-94 [11181450.001]
  • [Cites] Int J Oncol. 2001 Jun;18(6):1307-13 [11351267.001]
  • [Cites] J Leukoc Biol. 2001 May;69(5):719-26 [11358979.001]
  • [Cites] Photochem Photobiol. 2001 Jun;73(6):600-4 [11421064.001]
  • [Cites] Photochem Photobiol. 2001 Jun;73(6):621-9 [11421067.001]
  • [Cites] J Invest Dermatol. 2001 Jul;117(1):147-50 [11442762.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 Oct 15;176(2):110-7 [11601887.001]
  • [Cites] Drugs. 2001;61(14):2035-63 [11735632.001]
  • [Cites] Photochem Photobiol. 2001 Dec;74(6):787-93 [11783934.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):314-46 [11839647.001]
  • [Cites] Carcinogenesis. 2002 Mar;23(3):499-510 [11895866.001]
  • [Cites] Sci STKE. 2003 Jan 28;2003(167):RE2 [12554854.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6349-56 [15342425.001]
  • [Cites] Arzneimittelforschung. 1968 Jun;18(6):688-96 [5755805.001]
  • [Cites] Arzneimittelforschung. 1974 Apr;24(4):466-71 [4408125.001]
  • [Cites] J Natl Cancer Inst. 1974 Nov;53(5):1333-6 [4139281.001]
  • [Cites] Proc Natl Acad Sci U S A. 1977 Dec;74(12):5574-8 [271984.001]
  • [Cites] Br J Clin Pharmacol. 1978 May;5(5):431-6 [656282.001]
  • [Cites] J Immunol. 1980 Jan;124(1):445-53 [6153101.001]
  • [Cites] Br Med J. 1979 Dec 8;2(6203):1461-6 [393355.001]
  • [Cites] Scand J Gastroenterol. 1982 Jun;17(4):517-21 [6753109.001]
  • [Cites] Science. 1983 Sep 23;221(4617):1256-64 [6351251.001]
  • [Cites] Immunol Rev. 1984 Aug;80:87-102 [6237978.001]
  • [Cites] Cancer Res. 1986 May;46(5):2203-7 [3516380.001]
  • [Cites] J Hepatol. 1989 Jul;9(1):105-13 [2671116.001]
  • [Cites] J Exp Med. 1989 Oct 1;170(4):1117-31 [2529340.001]
  • [Cites] Semin Dermatol. 1990 Mar;9(1):25-31 [2203440.001]
  • [Cites] J Invest Dermatol. 1990 Oct;95(4):436-40 [2120354.001]
  • [Cites] J Invest Dermatol. 1990 Nov;95(5):530-6 [2230216.001]
  • [Cites] Pharm Res. 1991 Feb;8(2):273-7 [1902564.001]
  • [Cites] Dermatol Clin. 1991 Oct;9(4):751-5 [1934649.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10124-8 [1946433.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7516-20 [1502162.001]
  • [Cites] J Exp Med. 1993 Apr 1;177(4):1199-204 [8096238.001]
  • (PMID = 20372777.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA105368-01; United States / NCI NIH HHS / CA / R03 CA105368; United States / NCI NIH HHS / CA / R03 CA105368-02; United States / NCI NIH HHS / CA / CA105368-02; United States / NCI NIH HHS / CA / CA105368-01; United States / NCI NIH HHS / CA / CA105368
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antioxidants; 0 / Carcinogens; 0 / Plant Extracts; 0 / Silymarin
  • [Other-IDs] NLM/ NIHMS184206; NLM/ PMC2852174
  •  go-up   go-down


91. Liutkeviciūte-Navickiene J, Mordas A, Simkute S, Bloznelyte-Plesniene L: [Fluorescence diagnostics of skin tumors using 5-aminolevulinic acid and its methyl ester]. Medicina (Kaunas); 2009;45(12):937-42
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Fluorescence diagnostics of skin tumors using 5-aminolevulinic acid and its methyl ester].
  • OBJECTIVE: The incidence of malignant skin tumors is rapidly increasing.
  • Early diagnosis, determining the margins of the tumor, is extremely important to achieve good treatment results.
  • We investigated fluorescence of protoporphyrin IX in skin carcinomas.
  • The study aimed to compare the effectiveness of topical 5-aminolevulinic acid and methyl-aminolevulinate in determining the exact margins of skin tumors.
  • MATERIALS AND METHODS: Fluorescence measurements were performed in 126 patients with malignant, premalignant, and benign skin lesions for detection of the margins of squamous cell carcinoma and basal cell carcinoma.
  • 5-Aminolevulinic acid or its methyl ester was applied to the skin lesion for 2-4 h, and the data of evaluated protoporphyrin IX fluorescence were correlated with the data of morphological tissue examination.
  • RESULTS: Malignant tissue shows a specific red fluorescence when illuminated with blue-violet light, whereas no fluorescence was observed in normal skin.
  • A sensitivity of 95.4% and a specificity of 88.6% as well as positive and negative predictive values of 86.1% and 96.3%, respectively, were obtained.
  • CONCLUSIONS: Fluorescence diagnostics can be used for complete visualization of malignant skin lesions after topical application of 5-aminolevulinic acid or methyl aminolevulinate.
  • It has been shown to be highly effective in the diagnostics of malignant superficial skin lesion.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Fluorescence. Head and Neck Neoplasms / diagnosis. Photosensitizing Agents. Precancerous Conditions / diagnosis. Protoporphyrins. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Esters. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Sensitivity and Specificity. Skin / pathology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20173396.001).
  • [ISSN] 1648-9144
  • [Journal-full-title] Medicina (Kaunas, Lithuania)
  • [ISO-abbreviation] Medicina (Kaunas)
  • [Language] lit
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Lithuania
  • [Chemical-registry-number] 0 / Esters; 0 / Photosensitizing Agents; 0 / Protoporphyrins; 0 / methyl 5-aminolevulinate; 553-12-8 / protoporphyrin IX; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


92. Ullah T, Gurwood AS, Myers MD: Ocular metastasis of cutaneous malignant melanoma. Optometry; 2009 Oct;80(10):572-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ocular metastasis of cutaneous malignant melanoma.
  • Patients at greatest risk often have disseminated metastases in the setting of advanced disease.
  • Because the prognosis for orbital metastatic disease is poor, emphasis must be placed on early detection and prevention.
  • Although cutaneous malignancies include basal cell carcinoma, squamous cell carcinoma, sebaceous cell carcinoma, and malignant melanoma, the majority of cases that result in metastasis, ocular morbidity, and mortality are from sebaceous cell carcinoma and malignant melanoma.
  • Her systemic medical history was significant for the diagnosis of a cutaneous malignant melanoma.
  • Magnetic resonance imaging confirmed the diagnosis of metastatic lesions involving structures of the left orbit ultimately causing reduced visual ability.
  • Although orbital metastasis is considered a terminal finding in these cases, timely diagnosis enables, while limited, the best options for management.
  • [MeSH-major] Melanoma / secondary. Orbital Neoplasms / secondary. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Ocular melanoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19801341.001).
  • [ISSN] 1558-1527
  • [Journal-full-title] Optometry (St. Louis, Mo.)
  • [ISO-abbreviation] Optometry
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Braga JC, Scope A, Klaz I, Mecca P, González S, Rabinovitz H, Marghoob AA: The significance of reflectance confocal microscopy in the assessment of solitary pink skin lesions. J Am Acad Dermatol; 2009 Aug;61(2):230-41
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The significance of reflectance confocal microscopy in the assessment of solitary pink skin lesions.
  • BACKGROUND: Solitary pink lesions often manifest nondescript clinical and dermatoscopic primary morphologic features.
  • The differential diagnosis for pink lesions tends, therefore, to be broad, ranging from inflammatory processes to malignancy.
  • OBJECTIVE: We sought to demonstrate the use of RCM as an adjunct to the bedside diagnosis of pink lesions.
  • METHODS: We describe a series of patients with clinically and dermatoscopically equivocal pink lesions for which RCM examination allowed for a rapid and accurate diagnosis.
  • RESULTS: Lesions included basal cell carcinoma, squamous cell carcinoma, amelanotic melanoma, and inflamed seborrheic keratosis.
  • In the cases presented RCM allowed for a rapid and accurate noninvasive diagnosis.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Keratosis, Actinic / pathology. Melanoma / pathology. Microscopy, Confocal. Pigmentation Disorders / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy, Needle. Dermoscopy / methods. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Sampling Studies. Sensitivity and Specificity


94. Akyol M, Ozçelik S: Non-acne dermatologic indications for systemic isotretinoin. Am J Clin Dermatol; 2005;6(3):175-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diseases such as psoriasis, pityriasis rubra pilaris, condylomata acuminata, skin cancers, rosacea, hidradenitis suppurativa, granuloma annulare, lupus erythematosus and lichen planus have been shown to respond to the immunomodulatory, anti-inflammatory and antitumor activities of the drug.
  • Isotretinoin also helps prevent skin cancers such as basal cell carcinoma or squamous cell carcinoma.
  • A combination of systemic isotretinoin and interferon-alpha-2a may provide a more potent effect than isotretinoin alone in the prevention and treatment of skin cancers.Systemic isotretinoin may be considered as an alternative drug in some dermatologic diseases unresponsive to conventional treatment modalities.
  • [MeSH-major] Anti-Infective Agents / therapeutic use. Anti-Inflammatory Agents / therapeutic use. Dermatologic Agents / therapeutic use. Isotretinoin / therapeutic use. Skin Diseases / drug therapy
  • [MeSH-minor] Acne Vulgaris / drug therapy. Anti-Bacterial Agents / therapeutic use. Condylomata Acuminata / drug therapy. Drug Therapy, Combination. Granuloma Annulare / drug therapy. Hidradenitis Suppurativa / drug therapy. Humans. Keratolytic Agents / therapeutic use. Lichen Planus / drug therapy. Lupus Erythematosus, Systemic / drug therapy. Pityriasis Rubra Pilaris / drug therapy. Psoriasis / drug therapy. Rosacea / drug therapy. Sebaceous Glands / drug effects. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943494.001).
  • [ISSN] 1175-0561
  • [Journal-full-title] American journal of clinical dermatology
  • [ISO-abbreviation] Am J Clin Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Infective Agents; 0 / Anti-Inflammatory Agents; 0 / Dermatologic Agents; 0 / Keratolytic Agents; EH28UP18IF / Isotretinoin
  • [Number-of-references] 133
  •  go-up   go-down


95. Cunneen TS, Yong JL, Benger R: Lung metastases in a case of metatypical basal cell carcinoma of the eyelid: an illustrative case and literature review to heighten vigilance of its metastatic potential. Clin Exp Ophthalmol; 2008 Jul;36(5):475-7
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for metatypical basal cell carcinoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung metastases in a case of metatypical basal cell carcinoma of the eyelid: an illustrative case and literature review to heighten vigilance of its metastatic potential.
  • Basal cell carcinoma (BCC) is an extremely common malignancy; however, unlike other skin cancers, they very rarely metastasize.
  • Here we present an unusual case of metatypical BCC of the eyelid which metastasized to the lung nine years after initial surgical treatment.
  • We include a review of the literature regarding metastatic BCC and suggest that metatypical features in primary BCC should prompt careful patient monitoring and consideration of adjuvant treatment at the time of diagnosis.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / secondary. Eyelid Neoplasms / pathology. Lung Neoplasms / pathology. Lung Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18925916.001).
  • [ISSN] 1442-9071
  • [Journal-full-title] Clinical & experimental ophthalmology
  • [ISO-abbreviation] Clin. Experiment. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 13
  •  go-up   go-down


96. Park K, Lee JH: Bcl-XL protein is markedly decreased in UVB-irradiated basal cell carcinoma cell lines through proteasome-mediated degradation. Oncol Rep; 2009 Mar;21(3):689-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-XL protein is markedly decreased in UVB-irradiated basal cell carcinoma cell lines through proteasome-mediated degradation.
  • There is considerable evidence that the excessive ultraviolet radiation B (UVB) from sunlight is implicated in skin damage, ultimately inducing the death of keratinocytes.
  • If the apoptotic pathway does not work properly, the damaged cells have a chance to transform into a carcinoma, such as basal cell carcinoma or squamous cell carcinoma of the skin.
  • To develop a strategy of inducing apoptosis of skin cancer cells, the current study was performed to investigate the apoptotic pathway, especially focused on Bcl2 family proteins, in curcumin or UVB-treated basal cell carcinoma cell lines.
  • Our data demonstrated that the expression of Bcl-XL protein was decreased by proteasome-mediated degradation prior to change of mRNA level in UVB-induced apoptotic basal cell carcinoma cell lines, thereby these results will offer fundamental information to develop a strategy of inducing apoptosis of skin cancer cells.
  • [MeSH-major] Apoptosis / radiation effects. Carcinoma, Basal Cell / metabolism. Proteasome Endopeptidase Complex / radiation effects. bcl-X Protein / radiation effects
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Blotting, Western. Cell Line, Tumor. Cell Proliferation / radiation effects. Curcumin / pharmacology. DNA Fragmentation. Gene Expression / radiation effects. Humans. Reverse Transcriptase Polymerase Chain Reaction. Ultraviolet Rays. bcl-2-Associated X Protein / radiation effects. bcl-Associated Death Protein / radiation effects

  • Hazardous Substances Data Bank. CURCUMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212627.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BCL2L1 protein, human; 0 / bcl-2-Associated X Protein; 0 / bcl-Associated Death Protein; 0 / bcl-X Protein; EC 3.4.25.1 / Proteasome Endopeptidase Complex; IT942ZTH98 / Curcumin
  •  go-up   go-down


97. Kummoona R: Periorbital and orbital malignancies: methods of management and reconstruction in Iraq. J Craniofac Surg; 2007 Nov;18(6):1370-5
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor types were squamous cell carcinoma, basal cell carcinoma, conjunctival squamous cell carcinoma, retinoblastoma, fibrosarcoma, and ectopic mixed tumor in two, one, two, one, one, and one patients, respectively, in addition to eight patients with jaw lymphoma involving the orbit, out of 24 patients reported by us.
  • Surgery consisted of complete excision of orbital content (exenteration) with or without partial orbitectomy in four patients and wide excision of the tumor in four patients.
  • Reconstruction of the defect was accomplished using various local skin flaps and temporalis muscle flap was used for augmenting the orbit in the four exenterated patients.
  • There is no single best method for reconstruction of the periorbital and orbital defects left after tumor resection, and different flaps applied for reconstruction had given satisfactory results related to the type and complexity of the deformity.
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Child. Child, Preschool. Eye Enucleation. Female. Humans. Infant. Iraq. Lymphoma / chemistry. Lymphoma / surgery. Male. Middle Aged. Radiotherapy, Adjuvant. Skin Transplantation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17993883.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Babilas P, Landthaler M, Szeimies RM: Photodynamic therapy in dermatology. Eur J Dermatol; 2006 Jul-Aug;16(4):340-8
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Currently, topical photodynamic therapy (PDT) has received approval for the treatment of dermato-oncologic conditions like actinic keratoses, Bowen's disease, in-situ squamous cell carcinoma and basal cell carcinoma in many countries all over the world.
  • Due to the easy accessibility of skin to light activation, incoherent lamps or LED arrays are suitable for PDT.
  • Either cytotoxic effects resulting in tumor destruction or immunomodulatory effects improving inflammatory skin conditions are induced.
  • Treating superficial non-melanoma skin cancer, PDT has been shown to be highly efficient despite the low level of invasiveness.
  • [MeSH-major] Photochemotherapy. Skin Diseases / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Carcinoma, Basal Cell / drug therapy. Humans

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16935788.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 80
  •  go-up   go-down


99. Szeimies RM, Morton CA, Sidoroff A, Braathen LR: Photodynamic therapy for non-melanoma skin cancer. Acta Derm Venereol; 2005;85(6):483-90
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy for non-melanoma skin cancer.
  • Photodynamic therapy is a treatment modality that has been shown to be effective mainly for the dermato-oncologic conditions: actinic keratosis, Bowen's disease, in situ squamous cell carcinoma and basal cell carcinoma.
  • For actinic keratosis and basal cell carcinoma, methyl aminolevulinate-photodynamic therapy is already approved in Europe, Australia and New Zealand, and is now also approved for actinic keratosis in the US.
  • [MeSH-major] Photochemotherapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Bowen's Disease / drug therapy. Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Humans. Photosensitizing Agents

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16396794.001).
  • [ISSN] 0001-5555
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Photosensitizing Agents
  • [Number-of-references] 51
  •  go-up   go-down


100. Galloway TJ, Morris CG, Mancuso AA, Amdur RJ, Mendenhall WM: Impact of radiographic findings on prognosis for skin carcinoma with clinical perineural invasion. Cancer; 2005 Mar 15;103(6):1254-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of radiographic findings on prognosis for skin carcinoma with clinical perineural invasion.
  • BACKGROUND: The objective of the current study was to correlate pretreatment computed tomography and magnetic resonance imaging studies with outcomes for patients with squamous or basal cell carcinoma of the skin and clinical perineural invasion.
  • Patients were stratified as follows: imaging negative, 10 patients; minimal or moderate peripheral disease, 14 patients; and central and/or macroscopic disease, 21 patients.
  • RESULTS: The 5-year local control rates were as follows: imaging negative, 76%; minimal or moderate peripheral disease, 57%; and central and/or macroscopic disease, 25%.
  • The 5-year absolute and cause-specific survival rates were as follows: imaging negative, 90% and 100%, respectively; minimal or moderate peripheral disease, 50% and 56%, respectively; and central and/or macroscopic disease, 58% and 61%, respectively.
  • Patients who had imaging-positive minimal or moderate peripheral disease had a better local control rate but a similar survival rate compared with patients who had central and/or macroscopic disease.
  • [MeSH-major] Carcinoma, Basal Cell / radiography. Carcinoma, Squamous Cell / radiography. Neoplasm Invasiveness / pathology. Skin Neoplasms / radiography
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Assessment. Sampling Studies. Sensitivity and Specificity. Sex Factors. Survival Analysis. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15693020.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement